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PD Parkinson’s disease 
SN Substantia nigra 
SNpc Substantia nigra pars compacta 
SNpr Substantia nigra pars reticulata 
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MR Magnetic resonance 
DTI Diffusion tensor imaging 
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TYR tyrosinase  
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DA dopamine 
IR inversion-recovery  
STIR short T1 inversion recovery  
MT magnetization transfer 
ROI region-of-interest 
VBM voxel based morphometry 
VBA voxel-based analysis  
TBSS tract-based spatial statistics 
  










In the last years, extensive developments in neuroimaging MR techniques have 
profoundly changed the study of Parkinson’s disease (PD), evolving from the role of 
excluding secondary parkinsonism to the emergence as a disease biomarker. MR 
advanced sequences in high field magnets opened the possibility to visualize in vivo the 
substantia nigra (SN) and to investigate specific PD pathological changes, enabling the 
development of high accuracy tools for disease diagnosis in early stages and for the 
comprehension of disease pathophysiology. 
Our work was centered on the application of new MR imaging techniques to study the SN 
in PD, early in the disease course, mainly focusing on untreated patients at the time of 
clinical diagnosis. The primary objectives were centered on the application of high field 
MR imaging sequences in two main areas: diagnosis of PD in early disease stages and 
differential diagnosis with Essential tremor (ET). 
The development and application of neuromelanin sensitive MR imaging in 3.0 Tesla 
allowed the detection of significant changes in the SN of PD patients, with high sensitivity 
and specificity for disease diagnosis, even in early disease stages (namely at the time of 
clinical diagnosis). These imaging findings reproduced in vivo the characteristic 
pathological changes of PD with greater alteration in the ventrolateral SN region and 
preservation of the dorsal segment. These results were obtained with several image 
evaluation methods: semi-automated area assessments, manual width measurements 
and simple visual inspection by Neuroradiologists, corroborating the reproducibility of the 
data and enabling wider applications of this image technique in the clinical practice. 
The MR correlation of neuromelanin with iron in the SN of PD patients allowed the in vivo 
investigation of the influence of local iron concentration in the SN on the signal of 
neuromelanin-sensitive sequences. A quantification T2-relaxometry study showed that 
the SN paramagnetic iron effects do not seem to influence significantly the neuromelanin 
MR signal reduction in PD patients.  
Several studies with diffusion tensor MR imaging (DTI) have allowed the detection of 
microstructural changes in the SN of PD patients in early disease changes, emerging as a 
possible disease biomarker. So, the reproducibility of DTI metrics in this specific brain 
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area was particularly relevant for future applications of this MR technique. We conducted 
a reproducibility DTI study in PD patients that showed a good reproducibility of DTI 
metrics supporting the use of these measurements in further studies, namely longitudinal 
within-subject evaluation, and cross-sectional comparisons.  
The differential diagnosis of PD with ET is particularly relevant and there was the need of 
high accurate tools to aid the clinical assessment. The application of neuromelanin-
sensitive MR techniques was able to discriminate ET from early stage tremor-dominant 
PD with high sensitivity and specificity values, in the same range as nuclear medicine 
techniques and may become a useful clinical tool in the evaluation of tremor disorders.  
Our research showed an important role of neuromelanin sensitive MR imaging for the 
diagnosis PD in early disease stages and its differential diagnosis with ET. A multi-modal 
MR approach with iron assessment and diffusion tensor imaging can further elucidate the 
SN disease changes and aid future research of disease pathophysiology. 
 
 
Key-words: Parkinson’s disease, MRI, neuromelanin, iron, diffusion tensor imaging, 
Essential tremor. 
  






Nos últimos anos, o extenso desenvolvimento das técnicas de neuroimagem modificou 
profundamente a investigação da Doença de Parkinson (PD), evoluindo de um simples 
papel na exclusão de parkinsonismo secundário para a emergência de biomarcadores 
imagiológicos da doença. Sequências avançadas de RM em aparelhos de alto campo 
magnético abriram a possibilidade de visualizar in vivo a substantia nigra (SN) e a 
investigação de alterações patológicas específicas da PD, permitindo o desenvolvimento 
de ferramentas com elevada fiabilidade para o diagnóstico em fases precoces da evolução 
da doença e para a compreensão da sua fisiopatologia.  
A nossa investigação centrou-se na aplicação de novas técnicas de imagem RM para 
estudar a SN na PD, em fases precoces da doença, com  enfoque especial em doentes não 
tratados na altura do diagnóstico clínico. Os objectivos principais centraram-se na 
aplicação de sequências de RM em alto campo em duas áreas major: diagnóstico da PD 
em fases precoces da doença e o diagnóstico diferencial com o Tremor essencial (ET). 
O desenvolvimento e aplicação da imagem RM sensível à neuromelanina em 3.0T 
permitiu a detecção de alterações significativas na SN de doentes com PD, com elevada 
sensibilidade e especificidade para o diagnóstico da doença, mesmo em fases precoces da 
sua evolução dela (nomeadamente na altura do diagnóstico clínico). Estes achados de 
imagem reproduziram in vivo as alterações patológicas características da PD, com uma 
maior alteração na região ventero-lateral da SN e preservação do segmento dorsal. Estes 
resultados foram obtidos com vários métodos de avaliação de imagem: avaliação semi-
automática da área, medição manual da espessura e avaliação visual por 
neurorradiologistas, corroborando a reproductibilidade dos dados e permitindo uma 
aplicação abrangente desta técnica de imagem na prática clínica. 
A correlação por RM da neuromelanina com o ferro, na SN de doentes com PD, permitiu a 
investigação in vivo da influência da concentração local de ferro na SN com o sinal das 
sequências sensíveis à neuromelanina. Um estudo quantitativo de relaxometria T2* 
mostrou que os efeitos paramagnéticos do ferro não influenciam significativamente a 
redução de sinal RM da neuromelanina em doentes com PD.  
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Vários estudos com tensores de difusão (DT) permitiram a detecção de alterações 
microestruturais na SN de doentes com PD em fases precoces de doença, emergindo 
como um possível biomarcador de doença. Assim, a reproductibilidade das métricas de 
DTI, nesta área específica do encéfalo, é particularmente relevante para aplicações 
futuras desta técnica de RM. Conduzimos um estudo de reproductibilidade de DTI em 
doentes com PD que demonstrou uma boa reproductibilidade das métricas de DTI, 
suportando a utilização destas medidas em estudos futuros, nomeadamente avaliações 
longitudinais “within-subject” e comparações “cross-sectional”. 
O diagnóstico diferencial da PD com ET é particularmente relevante e ferramentas fiáveis 
para auxiliar a avaliação clínica eram necessárias. A aplicação de técnicas de RM sensíveis 
à neuromelanina possibilitou a discriminação de ET de PD “tremor-dominant” em fases 
precoces com elevados valores de sensibilidade e especificidade, no mesmo espectro das 
técnicas de medicina nuclear e pode tornar-se uma ferramenta clínica útil para a 
avaliação do tremor. 
A nossa investigação demonstrou um importante papel das técnicas de RM sensíveis à 
neuromelanina para o diagnóstico de PD em fases precoces da doença e para o seu 
diagnóstico diferencial com ET. Uma abordagem multi-modal de RM com avaliação do 
ferro e DTI pode, adicionalmente, permitir estudar as alterações da SN e auxiliar a 
investigação futura da fisiopatologia da doença. 
 
Palavras-chave: Doença de Parkinson, MRI, neuromelanina, ferro, imagem por tensores 
de difusão, Tremor essencial. 
  





















Extensive developments of neuroimaging techniques in the last years have profoundly 
changed the study of Parkinson’s disease (PD). In the past, computed tomography (CT) 
and magnetic resonance (MR) in PD were almost exclusively confined to the detection of 
secondary causes of parkinsonism. However, advanced MR sequences and high field 
magnets have revolutionized the in vivo study of the brain parenchyma, increasing signal-
to noise ratios, improving spacial and contrast resolutions and allowing microstructural 
evaluation.  
Recent advances in the understanding of PD pathogenesis have stimulated a great 
interest in the development of potential disease modifying therapies, and therefore, a 
more urgent need to detect disease as early as possible, to develop biomarkers that can 
assess the result of the interventions, and even allow an in vivo assessment of the 
processes involved in disease pathogenesis. 
The increased volume of research in the neuroimaging of PD, analyzing morphological 
and microstructural changes, opens a new path for the development of high accuracy 
diagnostic tools in early disease stages and for the comprehension of pathophysiological 
mechanisms, possibly allowing the development of imaging biomarkers with direct impact 
in the clinical practice. The increased interest in pre-manifest PD highlights the need to 
investigate pathological changes that occur very early in the course of the disease, before 
the beginning of clinical symptoms. MR imaging methods may significant contribute to 
study in vivo these changes and become very relevant in the detection of precocious 
disease alterations. Structural MR imaging appears also as the most promising marker of 
disease progression which may have a significant impact on the comprehension of 
disease progression, clinical correlations and the investigation of therapeutical effects.  
The expected rise in PD incidence over the next years additionally motivates research in 
this area.  Currently, PD has an estimated prevalence of 1% in the European population 
(1) and approximately 1,5 million in the United States (2). A recent study determined PD 
prevalence in Portugal to be around 18.000 patients (Nilza Gonçalves, Joaquim J. Ferreira, 
personal communication, February 26, 2015). The risk of developing PD increases 
significantly after 60 years of age and so, in the next 25 years, disease incidence is 
expected to significantly increase (2).  
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Parkinson’s disease (PD), first described in 1817 by James Parkinson (3), was traditionally 
seen as a specific neurodegenerative chronic progressive disease with specific clinical 
presentation and pathological findings. However what is designated as “idiopathic PD” 
might in fact be a heterogeneous group of changes, with diverse susceptibility factors and 
a wide genetic and phenotypic heterogeneity (4)1.  
Although PD is characterized by cardinal motor symptoms of bradykinesia, rigidity, tremor 
and postural instability (5,6), non-motor symptoms are growingly relevant in disease 
associated morbidity (7,8). Olfactory changes, depression, cognitive impairment, 
autonomic dysfunction and sleep disorders reflect the global brain involvement of PD 
(7,8). Imaging studies can provide significant insights into the comprehension of motor 
and non-motor complications of PD unveiling the diffuse brain changes of the disease. 
The characteristic topographic brain involvement of PD, with an ascending path from the 
brainstem to the neocortex (9) (Table 1), might be related to the susceptibility of 
neuronal types (9) to the accumulation of the inclusion Lewy bodies, abnormal 
aggregates mainly constituted of α-synuclein (α-Syn) and ubiquitin (10). 
 
Table 1. Main evolution stages of pathology changes in PD (9) 
 
Stages Main structre involved  Location of the lesions on pathology studies 
Stage 1 Medulla Dorsal IX/X motor nucleus and/or intermediate reticular zone 
Stage 2 Medulla and pons 
tegmentum 
Stage 1 + raphe nuclei, gigantocellular reticular nucleus, and 
coeruleus-subcoeruleus complex  
Stage 3  Midbrain Stage 2 + midbrain lesions, in particular SNc 
Stage 4 Prosencephalum and 
mesocortex 
Stage 3 + prosencephalic lesions; mesocortex and allocortex  
Stage 5 Neocortex Stage 4 + sensory association areas of the neocortex and prefrontal 
neocortex 
Stage 6 Neocortex Stage 5 + sensory association areas of the neocortex and premotor 
areas, occasionally mild changes in primary sensory areas and the 
primary motor field  
 
 
The characteristic depletion of substantia nigra (SN) dopaminergic and locus coeruleus 
(LC) noradrenergic neurons in PD (9,11-13) leads to a denervation of the striatum and 
                                                          
1 In spite of the recent controversy regarding the precise meaning of the term “Parkinson’s disease” and the 
most appropriate terminology to characterize disease variants (4) in this work we will use the term PD 
regardless of its variants, since there is no wide consensus as to the definitions in this field. 
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additionally to extensive extra-nigral pathology (9). In PD the SN changes are not uniform 
being characterized by a more pronounced reduction of dopaminergic cells in the 
ventrolateral segment (14) with a corresponding loss of dopaminergic innervation in the 
posterior putamen (15).  
PD becomes clinically manifest when the SN pathological changes have reached an 
advanced stage (16) being estimated that a degeneration of more than 50% of the 
dopaminergic SN neurons occurs before the beginning of motor symptoms (17). So most 
of the disease process has already occurred by the time the patient has clinical 
complaints, emphasizing the need for early and even pre-manifest disease studies. 
The diagnosis of PD in early disease stages has a great clinical relevance for the 
implementation of an adequate therapeutical plan, for prognostic definition and even for 
the appropriate selection of patients in clinical trials (18). But in spite of the established 
PD diagnostic clinical criteria (19), the differentiation with other causes of tremor and 
parkinsonism can be challenging, especially in early disease stages where a significant 
clinical overlap can occur (20). In atypical/uncertain cases the exclusive use of clinical 
criteria for PD diagnosis can have a high rate of misdiagnosis, even if performed by 
movement disorders specialized neurologists (21,22).  
So, imaging techniques might be of great importance, aiding diagnosis in early or pre-
manifest stages, helping to monitor disease progression and the therapeutical response 
and allowing the in vivo visualization of the characteristics disease patterns for the 
differentiation of parkinsonian syndromes (23). 
MR imaging approaches, including anatomical studies of connectivity and shape analysis, 
the evaluation of iron deposition in-vivo or microstructural diffusion changes, are 
increasingly relevant in PD.  
In this work we used a combined multimodal MR imaging protocol to study PD patients 
focusing on early-stage disease diagnosis and the differentiation of PD with essential 
tremor (ET). The study of neuromelanin with MR sensitive sequences assumed a 
particular relevance in PD early disease diagnosis, offering the possibility to image in vivo 
specific disease pathological changes and was complemented by a quantitative 
assessment of the iron content and microstructural diffusion tensor imaging, enabling a 
multifaceted study of PD pathological processes.    
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So we developed a multi-modal advanced MR imaging protocol focusing on the 
implementation, data analysis, evaluation of clinical impact and correlation with 
anatomical and pathophysiological PD changes of MR sensitive neuromelanin imaging for 
the diagnosis of early-stage PD patients, complementing this study with iron 
quantification and diffusion tensor imaging.   
 
  























The principal aim of this work was the implementation of a multimodal MR imaging 
protocol to study the SN in PD, focusing on early-stage patients at the time of clinical 
diagnosis, analyzing data in two main areas: disease diagnosis and differentiation with ET. 
 
The specific aims of this work were: 
 
 Analysis of MR neuromelanin changes in the SN of PD patients in early disease 
stages, determining the accuracy of this imaging technique for disease diagnosis;   
 
 MR study of the iron content of the SN in PD patients and it’s correlation with 
neuromelanin MR signal changes; 
 
 Microstructural evaluation of the SN with diffusion tensor imaging, determining 
the reproducibility of this imaging technique in PD patients; 
 
 Analysis of accuracy of MR SN neuromelanin imaging for the differential diagnosis 
of PD with ET;   
 
 Development of post-processing tools and evaluation methods to allow the clinical 
usage of these imaging techniques. 
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1. MR IMAGING OF PARKINSON’S DISEASE 
 
  








1.1. MR conventional sequences 
Conventional MR sequences, T1- or T2-weighted, do not allow a clear morphological 
identification of the SN, do not separate the two anatomical and functionally distinct 
areas - the SN pars compacta (SNc) and SN pars reticulata (SNr) - and are not able to 
detect the SN PD pathological changes (24). In T2-weighted images the SN has a 
characteristic low signal compared to the surrounding midbrain, but this hypointense 
area does not correspond to the SNc (25), extending anteriorly into the antero-medial 
crus cerebri, indistinguishable from the sub-thalamic nucleus. Several MR techniques have 
tried to improve SN visualization, namely through the increase of contrast with inversion-
recovery sequences (IR) (26,27), short T1 inversion recovery (STIR) (24) and magnetization 
transfer (MT) (28).  
 
 
1.2. MR advanced sequences 
In the last years a great number of MR advanced techniques have been used to 
investigate PD, accessing new morphological and structural information in vivo, especially 
in the evaluation of the SN and basal ganglia (29). However the data from the different 
studies are variable and have not allowed, in most cases, a significant accuracy for clinical 
application in disease diagnosis or progression monitoring. 
Diffusion weighted imaging studies using different methodologies (either ROI or VBM) 
have not been able to detect consistent changes in the diffusivity of the SN or the basal 
ganglia in PD patients (29,30).  
Spectroscopy studies in PD have also inconsistent findings which can be related with the 
low dimensions of the studied areas, namely in the SN, resulting in a great partial volume 
effect for each voxel (31). Very high field magnets, namely 7.0 or 9.0Tesla, increasing 
signal-to-noise ratios and spectrum resolution, might in the future allow the in vivo 
biochemical evaluation of the SN and other relevant areas for the study of PD. 
Functional MR studies have been widely used in PD, investigating changes in the motor 
networks. Using different methods especially recently developed techniques of resting-
state connectivity (32), these studies have depicted in vivo alterations of functional SN 
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connectivity. However in PD these imaging techniques are restricted almost exclusively to 
the clinical investigation field with reduced clinical implementation, which is also the case 
of perfusion studies with arterial RM de arterial spin labeling (33).  
 
1.2.1. Neuromelanin sensitive MR imaging 
In spite of the long known characteristic depigmentation of the SN in PD being related to 
the loss of the pigment neuromelanin (9), the investigation of the role of neuromelanin in 
the pathophysiology of PD is a new field of research. Projection neurons from the SNc and 
LC are characterized by the presence of a dark colored pigment, related to skin melanin, 
called neuromelanin (34).  
Neuromelanin is a substance originating from dopamine and noradrenaline metabolism 
and is though to have a protective role of neurons from oxidative stress mediated by free 
metals or free radicals (34,35). Following neuronal death neuromelanin can be released 
from neuropil (a complex network of axonal arborizations, dendrites and glia that forms 
most of the grey matter) or engulfed by macrophages (36).  
The role of neuromelanin in the etiology and pathophysiology of PD was highlighted by 
several epidemiology studies that described an increased incidence of melanoma in PD 
patients and vice versa (37-41). The largest prospective melanoma study in PD, with a 
total of 2106 patients, reported a seven times increase of the relative risk of melanomas 
in this population (38). Another study associated the diagnosis of melanoma to a 50% 
increased risk of subsequent PD development (42) and data from a study that included 
160 000 individuals without neurological disease has shown that individuals with a 
familiar history of melanoma have more that a double risk of developping PD (40). 
Epidemiology data additionally reports an increased incidence of PD (43-45) and of 
melanomas (46,47) in Caucasian populations compared to black individuals, indicating an 
increased vulnerability for the development of both skin tumors and PD associated with 
melanin skin concentration.  
The notion that melanosis potentially protects against melanomas and PD is additionally 
supported by the negative association between tobacco smoke and the incidence of PD, 
consistently found in numerous studies over the last 50 years (48-50). Smoker’s 
melanosis, a well documented phenomenon, is probably the result of increased melanin 
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synthesis related to the stimulation of melanocytes by nicotine or the bonding of melanin 
to noxious tobacco substances (51). 
Although the association between PD and melanomas is well documented the 
mechanisms of this association are not yet entirely known. The most accepted hypothesis 
implicates α-Syn which is known to play a crucial role in melanoma pathogenesis and PD. 
The relationship between melanin and α-Syn, which is expressed in normal skin (52) and 
in melanomas (53), has opened new perspectives in the pathophysiological research of 
PD. The melanin pigments are derived from the aminoacid tyrosine and the enzymes 
tyrosinase (TYR) and tyrosine hydroxylase (TH) are involved in the biosynthesis of melanin 
and dopamine initiated by the conversion of tyrosine to DOPA (54,55). These enzymes are 
present both in skin melanocytes and dopaminergic SN cells and exposure to ultra-violet 
light (UVB) enhances melanin synthesis and the activity of TYR and reduces extracelular 
DA in dopaminergic cells (56,57).  
The finding that α-Syn can interact with TYR (58) and inhibit TH (54,59) raises the 
possibility that α-Syn can play a role in the regulation of the biosynthesis of both melanin 
and DA.  
Therefore, in skin melanocytes of PD patients the increase in α-Syn inhibits TH decreasing 
melanin synthesis (53), with the consequent increase in melanoma risk. In dopaminergic 
neurons the interaction of TYR with increased levels of α-Syn changes the functions of this 
molecule inducing a toxic process with cytosolic DA and dopaquinone increased levels 
leading to mitochondrial damage and neuronal death (60). The association of α-Syn 
neurotoxicity with neuromelanin concentration changes (56,57) being the possible link 
between PD and melanoma has lead to a particular interest in the research of 
neuromelanin. 
In 2006 a Japanese group first described the application of a recently developed MR 
sequence that allowed the visualization of neuromelanin to the study of PD patients (61). 
In these patients there was a marked reduction of signal intensity in the regions 
corresponding to the LC and SN (62,63).  
We found this technique to be very promising for the direct visualization of pathological 
changes in PD. This imaging area was new and only initial reports had been published by 
the Japanese group, so we had to implement the MR sequence and the imaging analysis 
methodology. The initial MR sequence imaging parameters (61) had to be adjusted to the 
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available MR equipment  (RM 3.0T Philips Achieva) and in cooperation with Instituto de 
Biofísica e Engenharia Biomédica (IBEB) user interface tools were developed for imaging 
post-processing allowing the semi-authomated quantitative measurements of SN 
neuromelanin (Fig 1). 
 
 
Fig 1. Graphic user interface developed for the evaluation of MR sensitive neuromelanin images, with semi-
automated quantification tools for the SN high signal area (Matlab R2012a, The Math Works, Natick. 
Massachusetts, USA). 
 
So, we investigated the application of this MR technique to evaluate the SN of early-stage 
PD patients focusing in the diagnostic accuracy and the in vivo detection power of the 
pathophysiological changes of the disease. The growing recognition of the role of 
neuromelanin the PD pathophysiology combined with the possibility of visualization of 
this pigment using high field MR motivated our study were we ascertained the feasibility 
and determined the sensitivity and specificity of this imaging technique for “early-stage” 
PD diagnosis.  
The results of our study, with high accuracy of neuromelanin-sensitive MR imaging for 
early-stage PD diagnosis, opened the possibility for a wider use of this imaging techniques 
in further investigation trials with higher number of subjects but also in clinical practice. A 
wider use of this imaging technique needed easy and widely available imaging analyzing 
methods. So, we investigated the possible use of simple image analysis, comparing the 
visual inspection with a quantitative width analysis of the neuromelanin SN high signal 
area for PD diagnosis. 
 
 




1.2.2. MR evaluation of brain iron content 
Iron in the brain accumulates mainly as ferritin in oligodendrocytes, but can also be found 
in neurons and microglia, as shown in post-mortem studies, with higher concentration in 
the globus pallidus, SN, red nucleus, caudate and putamen (64). Dopaminergic neurons of 
the substantia nigra (SN) pars compacta (SNpc) and noradrenergic neurons of the locus 
coeruleus (LC) contain significant amounts of iron sequestered in neuromelanin granules 
(65). Approximately 20% of SN iron is bonded to neuromelanin in its ferric form (66) and 
the remainder is stored as ferritin and hemosiderin (67,68).  
In PD the SN iron content is increased (69,70), as demonstrated by several post-mortem 
studies, with higher iron levels in the individual neuromelanin granules of the nigral 
neurons (71). But the loss of these functional nigral neurons early in the course of the 
disease results in a general decrease in the number of neuromelanin granules, with iron 
being sequestered in Lewy bodies in SNpc neurons (72) and with an increased loading of 
ferritin with iron (73).  
Paramagnetic substances such as iron increase proton transverse relaxation rate (R2), 
shortening T2 but these signal changes are dependent on several factors other than 
concentration (74). In the brain tissue multiple iron interactions occur, possibly explaining 
the poor correlation between T2 times and direct measures of iron and ferritin, with 
factors other than iron having a role in determining the transverse relaxation parameters 
(75). 
Several MR techniques have been used to study the brain iron load, given the crucial role 
played by this element in a great number of biological processes namely DNA synthesis, 
gene expression, myelination or as a co-factor of several enzymes (such as TH), and its 
implication in neurodegeneration, including PD (76,77). MR studies with R2, R2* or R2’ 
relaxometry, determined by the transversal relaxation rate (T2 or T2*), correlate with 
post-mortem iron concentration, being very sensitive to evaluate and quantify brain iron 
content in vivo (78).  
A different MR imaging iron analysis with magnetic susceptibility weighted techniques 
(SWI) uses the information of magnetic susceptibility differences between regions to 
generate image contrast, combining both magnitude and phase information, and 
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although not allowing quantification, is very sensitive to alterations induced by the 
presence of paramagnetic substances such as iron (79).  
Both techniques have been used to study PD, trying to identify changes in the regional 
iron distribution and differences in the deposition patterns compared to other 
parkinsonian syndromes. Relaxometry studies using high field MR magnets have 
identified an increase in iron deposition in the SN corresponding to the characteristic 
pathological changes of the disease (80,81). SWI studies in PD have described an 
increased magnetic susceptibility in the SN, greater in the caudal segment (82) that 
allowed the identification of pattern differences with other parkinsonian syndromes (83).  
It is known that neuromelanin interacts with free iron in the SN and LC neurons acting as 
a strong protector in the delay of neuronal death (84-86). The interaction of 
neuromelanin with iron can render the SN dopaminergic neurons more susceptible to 
oxidative stress leading to neuronal damage (87-89).  
The interaction of neuromelanin with iron had not yet been studied and this was pointed 
out as a limitation to the analysis of neuromelanin-sensitive MR studies since the 
implication of the iron content to the T1 high signal in the SN of PD patients was not 
known. To answer this question we performed a combined MR imaging analysis of iron 
content, using quantitative relaxometry (Fig 2) and a neuromelanin-sensitive sequence to 
study of their interaction, influence and correlation.  
 
 
Fig 2. Graphic user interface developed for evaluation of MR relaxometry with quantification tools for the 
SN area (Matlab R2012a, The Math Works, Natick. Massachusetts, USA). 
 




1.2.3. Diffusion tensor imaging 
Diffusion tensor imaging (DTI) MR sequences have recently acquired a significant 
relevance in PD investigation. This technique is based in the analysis of water molecules 
diffusivity, using a mathematical tensor model to characterize diffusion in the 3D space, 
which has a variable degree according to the molecular characteristics of the tissue (90). 
DTI parameters allow an estimation of the degree of directionality through anisotropy 
(frequently fractional anisotropy FA) and the global movement of the molecules (mean 
diffusivityMD and apparent diffusion coefficient ADC). These measures can be 
obtained with multiple approaches either locally in predefined regions with ROI analysis 
or globally with voxel-based analysis (VBAA) or tract-based spatial statistics (TBSS). In the 
white matter diffusion is limited in certain directions being less dependent of direction in 
the grey matter where FA values are lower (90). Voxel-based DTI studies have been 
widely used to study white matter but also allow the detection of grey matter integrity 
changes (91).  
Tissue microstructural changes such as occur in neurodegenerative processes can be 
associated with alterations in anisotropy and diffusivity measures (91) and animal model 
studies have positively correlated DTI parameters with SN dopaminergic neuronal loss 
(92), giving and indirect measure of degeneration.  
A DTI study by Vaillancourt and colleagues (93) has gained a particular relevance because 
of the high sensitivity and specificity of the reported reduction of FA values in the SN for 
the distinction of early-stage PD patients from healthy controls; this data reproduced in 
vivo the pathology findings of selective dopaminergic neuronal loss in the ventrolateral 
and caudal segments of the SN (14). But several studies have used DTI to evaluate the SN 
in PD and the majority of the studies report an FA reduction in the SN, consistent with the 
characteristic pathological changes of the disease (23,94). Very recently a DTI study has 
even demonstrated microstructural SN changes in subjects chronically exposed to 
pesticides, which is a known risk factor associated with PD (95).  
So, these data seem to indicate that MR studies with DTI can detect SN changes that 
occur before clinical manifestations of the disease aiding early and even pre-clinical 
diagnosis and identifying disease risk factors and its etiological implication with the 
potential to become a non-invasive biomarker of PD. 
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DTI techniques have additionally allowed the study not only of nigro-striatal pathways 
and its projections (94), but also of the diffuse brain involvement in PD, identifying 
changes in the olfactory areas (96), basal ganglia (97), frontal white matter (98) or the 
corpus callosum (99), among many other regions. DTI tractography studies have also 
enabled the investigation of structural connectivity between brain regions, with 
descriptions of a reduced connectivity between the SN and the putamen/ipsilateral 
thalamus in PD patients (100).  
In spite of all the data, a recent meta-analysis of DTI studies in PD has concluded that 
there is still some inconsistency of the results in early-stage patients and that with the 
available data the conclusion as to the accuracy of this technique in terms of PD patient’s 
identification can not be drawn (23).   
Our imaging protocol included the microstructural study of the SN with DTI answering to 
the need to replicate the DTI data in the evaluation of SN changes in early-stage PD 
patients studying the reliability of the measurements with a reproducibility analysis. This 
had not yet been done in PD patients and this group of patients had specific 
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Abstract: The authors reviewed the diffusion tensor imaging (DTI) and tractography (DTT) of the 
normal brainstem and cerebellar white matter in normal volunteers, correlating it with structural 
magnetic resonance (MR) imaging and DTI data obtained in patients evaluated in our department 
with parkinsonian movement disorders, including multisystem atrophy (MSA), spinocerebellar 
ataxia (SCA), Progressive Supra-nuclear palsy (PSP) and idiopathic Parkinson’s disease (PD). Axial, 
sagital, coronal DTI and tractography data demonstrated major white-matter fibers within the 
brain stem and cerebellum, including cortico-spinal tracts, transverse pontine fibers, medial 
lemniscus and cerebellar peduncles. Visualization of the selective degeneration of these individual 













Diffusion tensor imaging (DTI) and diffusion tensor tractography (DTT) have been used to 
map the normal anatomy of the brainstem/cerebellum, not only of the white matter but 
also allowing the study of gray matter structures (101). DTI data has enabled detailed 
imaging of major afferent and efferent pathways of the cerebellum and their connections 
with the brainstem (101,102). The increased sensitivity of DTI in demonstrating changes 
in the brainstem and cerebellum white matter has been shown in a wide number of 
pathologies. This information combined with structural MR imaging has proven useful in 
the detection of impairment in extra-pyramidal circuits, particularly in movement 
disorders (103).  
The idiopathic parkinsonian movement disorders are a group of distinct 
neurodegenerative diseases, including idiopathic Parkinson’s disease (PD), and atypical 
parkinsonian disorders (APD), comprising multiple system atrophy (MSA), progressive 
supranuclear palsy (PSP) and corticobasal degeneration (CBD). In the early stages of 
disease, the differential diagnosis between PD and APD remains a clinical problem, with 
APD comprising up to 20% of patients presenting with parkinsonism (18). Although 
conventional magnetic resonance imaging (MR) can demonstrate changes in APD, these 
are essentially present in advanced stages of disease and have low specificity and 
sensitivity in the differential diagnosis (104).   
The potential of DTI combined with DTT for the differential diagnosis and evaluation of 
the neurodegeneration of specific pathways in parkinsonian disorders has highlighted DTI 
as a potential useful tool in the clinical routine (105,106).  
We reviewed DTI imaging of the normal brainstem and cerebellar white matter and the 
characteristic DTI patterns in the more frequent movement disorders. A retrospective 
review of the DTI studies performed in patients evaluated in Hospital de Santa Maria 
(Lisbon) with parkinsonian movement disorders was made, trying to ascertain the results 
obtained and correlating them with the published literature.  
 
Methods 
Retrospective review of structural MR imaging and DTI/DTT of brainstem and cerebellar 
white matter in healthy volunteers and patients with clinically proven parkinsonian 
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movement disorders including idiopathic Parkinson’s disease (PD), multisystem atrophy 
(MSA), corticobasal degeneration (CBD), spinocerebellar ataxia (SCA), and Progressive 
Supra-nuclear palsy (PSP), evaluated in Hospital de Santa Maria - Lisbon with DTI studies 
in the last two years. 
 
Subjects 
Two healthy volunteers aged 42 and 54 years, and thirteen patients with early/advanced 
stage MSA, PSP, CBD, SCA, and PD. The diagnosis was made clinically, using established 
criteria (18). Control and patient data are summarized in Table 1.  
 
Imaging protocol 
All the studies that we reviewed, were performed in a 3.0-T Philips MR scanner, using an 
eight channel head coil. DTI was performed with 5mm thickness using a single-shot EPI 
sequence. The diffusion encoding used in the studies varied between 15 or 24 directions 
(b values 0 - 800 s/mm2). In all the studies reviewed a T1-weighted and a T2-weighted 
axial scan have also been acquired.  
 
Post-processing 
DTI data were analysed using DTI Studio or the PRIDE fibre-tracking tool supplied by 
Philips Medical Systems. In all cases FA maps with grey-scale and colour coding were 
generated. The colour-coding was assigned as: red - left to right, blue – craniocaudal, 
green – rostral-dorsal directions.  
Using the same post-processing tools both single and multiple regions of interest (ROIs) 
were selected for tractography in the pons, midbrain or any particular anatomical 
structure. The tracts were visualized by setting the tractography colour algorithm to show 
the principal anisotropy and direction with a threshold FA of less than 0.2. 
 
Results 
Conventional Imaging data 
No anatomical or signal intensity abnormalities were seen in T1- and T2-weighted images 
in controls, patients with early MSA and PSP, the patient with PD or SCA1.  
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In the advanced MSA-C patients a significant atrophy of the pons and cerebellum was 
seen as well as T2 hyperintensity of the middle cerebellum peduncles and pontine 
cruciform signal. Small linear T2 hypointensity of the putamen was identified in patients 
with MSA-P and the “eye-of the tiger signal” and asymmetrical parietal atrophy in the 




Transverse fibers of the vermis were apparent in red and are visible in all sections (Fig. 1-
3). On parasagittal color maps the main tracts have a green color, with anteroposterior 
direction, connecting the cerebellar cortex and the emboliform and dentate nuclei (Fig. 
3). The inferior cerebellar peduncle (ICP) can be identified in coronal sections, with blue 
color, lateral to the medial lemniscus (Fig.4). The middle cerebellar peduncle (MCP) 
projects to pontine nuclei and appears as a large symmetric green area, clearly visible in 
all planes, intermingling with fibers of the dentate nucleus (Fig. 1-3, 5-6). The superior 
cerebellar peduncles (SCP) were easily identified in axial and sagittal planes (Fig.3, 6), and 
the decussation of the SCP was visible in red color on horizontal sections (Fig.7) at the 
level of the midbrain.  
 
Patients 
DTI imaging with FA and colour coded maps in MSA cases of the cerebellar type (MSA-C) 
showed a significant decreased in fractional anisotropy (FA) in the TPF and MCP, with 
preservation of the pyramidal tract and medial lemniscus (Fig.8), similar to the previous 
reported cases (107). In sagittal images of the brain stem, atrophy and severe 
degeneration of both the MCP and TPF could be seen in all patients with advanced MSA, 
which was not seen in any of the controls or other patient groups. In MSA of the 
parkinsonian type (MSA-P) there was a decrease in FA of the MCP with only a slight 
decrease in the pontocerebellar fibers (Fig.9).  
In PSP, we found a decreased FA in the SCP (significant in advanced cases and less 
prominent in early disease progression), as well as blue color decrease in the SCP and loss 
of the normal red color of the SCP decussation in the advanced case (Fig. 10); contrary to 
MSA cases there was relative integrity of TPF and MCP (108).  
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In the corticobasal degeneration patient we found only a slight FA decrease in the MCP, 
with no identifiable changes in the color coded map and no significant FA changes in the 
TPF or SCP. 
In SCA changes are reported as variable, not allowing the differentiation between the 
different subtypes (109) but differing from healthy controls. Some studies in SCA type 1 
and 2 have shown loss of cerebellar hemispheric fibers and decrease FA in the cerebellar 
peduncles and TPF (110), similar to what we found in a genetically confirmed SCA type 1 
case (Fig. 11).  
In Idiopathic Parkinson’s Disease (PD) we found FA reduction in the substancia nigra 
compared with one of the controls (Table 2), with a lateral to medial gradient, similar to 
the one found by Vaillancourt (93). 
 
Discussion 
Many studies have been published in the last 10 years investigating MR imaging in the 
differential diagnosis of parkinsonian disorders especially PD from the atypical disorders 
as MSA and PSP. Several morphological changes have been described as characteristic of 
MSA or PSP but, in general, these conventional MR signs have a low sensitivity for the 
diagnosis (104,111). Recently some studies using DTI/DTT have shown a greater 
sensitivity of this technique in the differential diagnosis of parkinsonian disorders 
compared to conventional MR, rendering it attractive not only for future research but 
introducing it into the clinical practice (105, 109).  
The results of our review, with a small number of patients, are in accordance with 
previous DTI data. In patients with late stage MSA we found the characteristic 
morphology changes especially prominent pontine/cerebellar atrophy, pontine cruciform 
sign and MCP signal changes (111). DTI data showed marked changes in the MCP and TPF 
in advanced cases but also FA and MCP/TPF color reduction in the early stages of the 
disease, similar to published studies (112), indicating that DTI data might be important in 
the distinction of MSA from controls as well as from PSP and Parkinson’s disease (113). 
The characteristic morphological MR changes of PSP were identified only on late stages of 
the disease, with prominent atrophy of the midbrain and SCP (114). Similar to previous 
studies (108) in our patient with advanced disease we found a decreased FA in the SCP 
and loss of the normal red color of the SCP decussation with relative integrity of the TPF 
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and MCP, enabling a differential diagnosis of this patient not only with controls but also 
with PD and MSA cases. 
Corticobasal degeneration (CBD) has a distinctive clinical picture in late stages of the 
disease, but diagnosis is often uncertain at disease onset (115), with studies showing 
incorrect clinical diagnoses as well as pathologic overlap with other neurodegenerative 
diseases, namely PSP (116). In late stages CBD has characteristic asymmetric 
frontoparietal atrophy with less consistent putaminal signal changes on MR studies (117), 
as was found in our patient. On DTI there was only a slight FA decrease in the MCP but 
there were no significant changes in the TPF or SCP as seen in late stages MSA or PSP. 
Conventional imaging differentiation of the different subtypes of SCAs is difficult and 
structural imaging can be normal in the early stages of the disease (109) with atrophy and 
signal changes of the brainstem and cerebellum appearing late in the disease (118). DTI 
studies in SCA have not enabled differentiation between SCA subtypes, namely SCA 1 and 
SCA2 but have shown strong differences with controls as was found in our case and 
correlating with clinical scores (109). 
PD is known for its paucity of abnormal findings on MRI (103). The DTI study of 
Vaillancourt (93) found changes in the substancia nigra (SN) in PD patients with a lateral 
to medial gradient that was also found in our only patient with recent onset PD.  
Diffusion tensor tractography is an excellent tool for imaging individual white matter 
tracts of the brainstem (112,119), however the technical limitations of this method need 
to be considered, especially the problems with concerning fiber crossing, delineation of 
tracts using manually drawn ROIs (120), distortion of axonal and neuronal architecture in 
neurodegenerative diseases, making it more difficult for the tracking algorithm to follow 
the fibres over longer distances or changes in direction. Tractography has also been less 
used in the study of movement disorders because data often require extensive manual 
postprocessing work, lacks standardization, are not easily reproducible for comparison. 
Our work was just a retrospective review with a very small number of patients, based only 
on clinical diagnosis with no neuropathology confirmation, intended to evaluate the 
protocols used, the applicability, feasibility and relevance in clinical cases of the results 
obtained with DTI and DTT as part of the MR investigation in the differential diagnosis of 
parkinsonian disorders. We found DTI changes in advanced as well as early cases that had 
normal morphological imaging; these changes enabled patient differentiation from 
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controls and MSA patients from PSP. However, there is the need for prospective studies 
with a significant number of patients trying to evaluate the sensitivity and specificity o DTI 
imaging in the diagnosis of parkinsonian movement disorders, especially in early stages of 
disease. 
In the majority of previous DTI studies field strengths of 1.5 T and fewer directions have 
mostly been used (112,119). In this review all the studies were performed in a 3.0T field 
strength, using 15 or 24 independent diffusion encoding directions in order to increase 
the directional resolution as well as being tolerable for the patient and less susceptible to 
movement artifacts. The limited data of our review do not enable us to draw any 
conclusions as to the number of optimal directions to be used. 
The DTI protocols we reviewed are easy to implement in a clinical setting, offering the 
possibility to study, in vivo, the major connections of the brainstem-cerebellum in healthy 
individuals as well as offering a unique possibility to study pathological changes 
unidentifiable in conventional MR sequences. In the cases we reviewed, DTI data (colour 
mapping and DTT) supplemented routine T1- weighted, T2-weighted and FLAIR images in 
the differential diagnosis of parkinsonian disorders. 
Although DTI/DTT have not yet become a routine procedure in the clinical setting, 
DTI/DTT protocols can be easily implemented and yield clinically relevant information. 
The different DTI pattern in movement disorders appears to be complementary to 
conventional structural MR (106), and in the future can be a useful tool for specific 
movement disorders identification in the clinical practice.   
Furthermore, quantitative data on the diffusion properties of specific white matter tracts 
can be elicited, which might be of use in future studies of disease progression and effects 
of treatment in future research. 
 
Conclusion 
DTI imaging is very useful in identifying the normal brainstem and cerebellar white 
matter. White matter water-molecule disturbance in the brain-stem and cerebellar fibers 
in different types of movement disorders can be identified by DTI and provide a 
functional evaluation of the impaired extra-pyramidal circuits. Our results are concordant 
with other series demonstrating that DTI is a useful tool in the evaluation of the status of 
white matter fibers and some gray matter structures, and in combination with structural 
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imaging may have diagnostic value in patients with movement disorders. Our limited 
review indicates that DTI with DTT may add qualitative information that together with 
conventional MRI aids in the differential diagnosis of parkinsonian movement disorders.  
 

















Control 42 M NA NA Normal Normal 
Control 54 F NA NA Normal Normal 
MSA-C 62 M MSA long - pontine-cerebellar atrophy 
- T2 hyperintensity MCP 
- pontine cruciform signal 
-  FA MCP and TPF 
- MCP atrophy/green color 
lost 
- TPF red color lost 
MSA-C 69 F Ataxia long - pontine-cerebellar atrophy 
- T2 hyperintensity MCP 
- pontine cruciform signal 
-  FA MCP and TPF 
- MCP atrophy/green color 
lost 
- TPF red color lost 
MSA-C 59 F Ataxia short - pontine-cerebellar atrophy -  FA MCP and TPF 
- MCP green color  
MSA-C  63 M Ataxia short Normal -  FA MCP and TPF 
- MCP green color 
MSA-C 72 F Ataxia short Normal  FA MCP and TPF 
- MCP green color 
MSA-P 71 M Atypical 
parkinsonism 
long Atrophy and T2/T2* 
hypointensity putamen 
-  FA MCP 
MSA-P 63 M Atypical 
parkinsonism 
short Normal -  FA MCP 
MSA-P 70 F Atypical 
parkinsonism 
short Normal (basal ganglia T2 
hypointensity normal for age 
group) 
-  FA MCP 
PSP 64 M Atypical 
parkinsonism 
long Midbrain atrophy -  FA SCP 
- SCP blue color lost 
- absence SCP decussation 
red color 
- normal MCP and TPF 
PSP 68 M Atypical 
parkinsonism 
short Normal -  FA SCP 
- SCP blue color reduction 
- SCP decussation red color 
reduction 
- normal MCP and TPF 




long - asymmetric parietal 
atrophy (left> right) 
- “eye of tiger” signal 
- T2 hyposignal external 
putamen 
-  FA MCP 
- normal TPF and SCP 
SCA1 56 M Ataxia long - pontine cerebellar atrophy -   cerebellar hemispheric 
fibers 
- FA MCP and TPF 
PD 62 M Parkinsomism short Normal - SN FA changes 
 
 
Table 2. Fraccional anisotropy values in ROIs placed in the SN (rostral, middle and caudal portions) in a 
healthy control and PD patient. In PD patient reduced FA was greater in the caudal compared with the 
rostral ROI. 
 
 FA values 
ROIs SN PD Control 
rostral 0,49 0,56 
middle 0,40 0,54 
caudal 0,42 0,60 





Figure 1. DTI on horizontal sections: at the level of upper medulla (A) the main cerebellar tracts, bellow the 
level of the dentate are visible by their green color. At the level of the mid part of the pons (B) the ascending 
fibers of the medial lemniscus and corticospinal tract can be followed easily; laterally the two middle 
cerebellar peduncles are outlined by their green color, around the dentate nucleus.1-middle leminscus. 2-
pyramidal tract. 3-transverse pontine fibers. 4-middle cerebellar peduncle. 5-vermian transverse fibers. 
 
 
Figure 2. DTI coronal sections of the cerebellum behind the floor of the IV ventricle (A) and more posterior, 
at the level of the dentate nucleus (B). The afferent fibers of the middle cerebellar peduncle and the fibers to 
the dentate are clearly visible. The afferent fibers of the dentate are visible on section B, located more 
posteriorly. 1-dentate  fibers. 2-middle cerebellar peduncle. 3-vermian transverse fibers. 
 
 
Figure 3. DTI sagittal sections of the brainstem and cerebellum on the midline (A), 5mm (B) and 10mm (C) 
from the midline. In the midline section almost all the vermian cerebellar surface corresponds to transverse 
fibers. More laterally the main fibers are directed from the cerebellar hemispheres to the main cerebellar 
nuclei. Above the level of the lateral part of the IV ventricle the superior cerebellar peduncle is well outlined. 
The two components of transverse pontine fibers are clearly visible by their red color. 1- transverse pontine 
fibers. 2-medial lemniscus 3-pyramidal tract.4-superior cerebellar peduncle. 5-inferior cerebellar peduncle. 6-
middle cerebellar peduncle. 7-hemispheric cortical fibers to dentate and emboliform nuclei. 
 





Figure 4. Selective tracking of the middle cerebellar peduncle on axial projection (ROI in the mid portion of 





Figure 5. Selective tracking of the middle and superior cerebellar peduncle (ROI in the mid pons).1- 
transverse pontine fibers. 2-medial lemniscus 3-pyramidal tract.4-superior cerebellar peduncle. 5-middle 





Figure 6. Selective tracking of the superior cerebellar peduncle (ROI in the superior cerebellar peduncle). 
 





Figure 7. DTI on horizontal sections of the superior pons (A) and midbrain (B). 1-superior cerebelar 





Figure 8. DTI horizontal section of the mid pons (A), coronal section of anterior pons (B), midline sagittal 
section (C) and tractography (D,E) in a patient with MSA-C showing significant decrease of the 
pontocerebellar fibers and transverse pontine fibers, with atrophy of the middle cerebellar peduncle. Relative 
integrity of pyramidal tract and medial lemniscus.  





Figure 9. DTI on horizontal sections of the inferior (A), mid pons (B) and midbrain (C) in a patient with 
MSA-P, showing slight decrease of pontocerebellar fibers, with decrease in FA of the middle cerebellar 






Figure 10. DTI on horizontal sections of the mid pons (A) and midbrain (B) in a patient with PSP, showing a 
thin superior cerebellar peduncle with no identifiable red color at the superior cerebellar peduncle 





Figure 11. DTI horizontal sections of the medulla (A), mid (B), superior pons (C), midbrain (D) and 
tractography (E) in a patient with SCA 1, showing decrease of transverse pontine fibers. Integrity of middle 










1.3. Multimodal imaging 
Integrating different imaging MR techniques might enhance diagnostic accuracy, as 
proposed by Péran and colleagues (121) in a study that combined information from 
volumetric analysis, iron content measured with R2* relaxometry, mean diffusivity and FA 
values in the SN to evaluate PD. 
The investigation of imaging biomarkers in PD assumes in our view a preponderant role, 
in view of the growing ability of MR studies to enable an in vivo access to the morphology 
and microstructure of the brain parenchyma. The conjoint use of multiple sequences 
might to allow a wide evaluation of different pathophysiological aspects, studying their 
















2. MR IMAGING FOR THE DIAGNOSIS  





















2.1. Substantia nigra neuromelanin magnetic resonance imaging in “de novo” 
Parkinson’s disease patients 
 
Reimão S, Pita Lobo P, Neutel D, Correia Guedes L, Coelho M, Rosa MM, Ferreira J, Abreu 
D, Gonçalves N, Morgado C, Nunes RG, Campos J, Ferreira JJ. 
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Background: Depigmentation of the substantia nigra (SN) and locus coeruleus (LC) is a 
conspicuous pathological feature of Parkinson’s Disease (PD) and is related to the loss of 
neuromelanin, whose paramagnetic properties result in high signal on specific T1-
weighted MRI. Recent studies have suggested that neuromelanin decrease in the SN and 
LC of PD patients may emerge as a possible diagnostic biomarker. We studied the SN 
neuromelanin signal in “de novo” and early stage PD patients to assess its diagnostic 
accuracy. This is the first study based on a semi-automated MRI analysis of the 
neuromelanin signal in “de novo” PD patients.  
Methods: The inclusion criteria were untreated “de novo” PD and a 2 – 5 year disease 
duration; in addition, age matched healthy controls were enrolled. These were studied 
with a high-resolution T1-weighted MR imaging sequence at 3 Tesla to visualize 
neuromelanin. The primary outcome was SN high signal area, length and 
neuromelanin/midbrain ratio obtained with semi-automated methods.  
Results: A total of 12 “de novo” PD patients and 10 PD patients with a 2 – 5 year disease 
duration were evaluated. The area, length of the SN T1 high signal and the SN 
neuromelanin/midbrain ratio were markedly decreased in the PD groups compared with 
age-matched controls, with a substantial overlap between the two PD groups.  
Conclusions:  Neuromelanin-sensitive MRI techniques can discriminate PD patients from 
healthy individuals with high sensitivity and specificity. Our findings are consistent with 
recent findings showing that PD neuromelanin changes remain stable during the course 
of the disease.   









Parkinson’s disease (PD) is a neurodegenerative condition characterized by depletion of 
dopaminergic neurons in the substantia nigra (SN) pars compacta (SNpc) and 
noradrenergic neurons in the locus coeruleus (LC) (11). Pathological changes in the LC and 
SN occur early in the course of PD and have been described in preclinical stages (9). 
Depigmentation of the SN and LC is a conspicuous pathological feature of PD and is 
related to the loss of a melanin pigment known as neuromelanin.  
Neuromelanin is a by-product of dopamine and noradrenaline metabolism and is thought 
to protect neurons from oxidative stress mediated by free metals or free radicals (35). 
This pigment has paramagnetic properties resulting in high signal on specific T1-weighted 
magnetic resonance imaging (MRI), enabling its identification in vivo (61,62). Recent 
studies have described a reduction in MRI neuromelanin-generated signal in the SN and 
LC in patients with PD (61,63).  
We examined neuromelanin-sensitive MR imaging in “de novo” untreated PD patients 
and in PD patients with a 2 – 5 year disease duration to study the diagnostic accuracy of 
this MRI sequence at clinical presentation and to determine whether it was possible to 
obtain objective measurements of SN T1 high signal area and length using semi-
automated methods that would discriminate PD patients from controls. 
To our knowledge, this is the first study based on neuromelanin semi-automated MR 
imaging in “de novo” untreated PD patients. 
 
2. Patients and methods 
2.1. Patients and control subjects  
The study was a cross-sectional case-control analysis (prospective follow-up ongoing) that 
included 32 subjects: 12 “de novo” patients with PD, 10 PD patients with a 2 to 5 year 
disease duration and 10 healthy subjects. Patients were recruited from the Movement 
Disorders Unit of the University Hospital of Santa Maria-Lisbon. “De novo” PD patients 
were included at the time of clinical diagnosis if they were not on antiparkinson 
medications, and all had less than 6 months since the beginning of clinical symptoms. PD 
patients with 2 to 5 year disease duration since clinical medical diagnosis were receiving 
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optimal pharmacotherapy with levodopa or dopamine agonists. All patients were 
diagnosed with PD by a movement disorders specialist according to the UK Brain Bank 
criteria (19) and were rated using the Unified Parkinson’s Disease Rating Scale (UPDRS). 
The healthy control subjects were recruited from local hospital staff and relatives. 
Dementia, psychiatric illness or contraindications to an MRI were the exclusion criteria. 
The examinations were performed with the understanding and written consent of each 
subject, with approval from the local ethics committee, and in compliance with national 
legislation and the Declaration of Helsinki guidelines. 
 
2.2. MRI protocol 
2.2.1. Imaging protocol 
All data were acquired with a 3.0-Tesla Phillips scanner (Phillips Achieva). The following 
pulse sequence was used as previously described by Sasaki and colleagues (61): T1-
weighted FSE: repetition time/effective echo time, 633/10; echo train length, 3; number 
of slices, 20; slice thickness, 2.5 mm; intersection gaps, 0 mm; matrix size, 548 x 474; field 
of view, 220 mm (pixel size: .40 x .40 mm); and acquisition time, 8 min. The sections were 
carefully set in the oblique axial plane perpendicular to the fourth ventricle floor with 
coverage from the posterior commissure to the inferior border of the pons.  
T1- and T2-weighted images of the entire brain were additionally obtained in all subjects 
and evaluated by an experienced neuroradiologist to exclude other pathological imaging 
findings, namely, changes in the parkinsonian index and other atypical parkinsonian 
syndrome changes, and lesions in the LC and SN areas that might interfere with further 
assessment. 
 
2.2.2. Imaging analysis  
Images were transferred to a Linux workstation for analysis, and an edge preserving filter 
(122) was applied using Matlab (R2012a, The Math Works, Natick. Massachusetts, USA) to 
reduce image noise. This is an adaptive mean filter, where the intensity of each pixel in 
the filtered image ?̂?(𝑖) is determined from the neighbourhood Vi of each pixel i (8 
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neighbours in 2D). The weight w(i,j) given to each neighbouring pixel depends on the 
intensity difference between i and its neighbour j: 
?̂?(𝑖) =
∑ 𝑤(𝑗 ∈ 𝑉𝑖 
𝑖,𝑗) 𝑢(𝑗)
∑ 𝑤(𝑗 ∈ 𝑉𝑖 
𝑖,𝑗)
  where 𝑤(𝑖, 𝑗) = 1 −
|𝑢(𝑗)−𝑢(𝑖)|
3×255
 and 𝑤(𝑖, 𝑖) = 0. 
In this way pixels with similar intensity levels are given a higher weight, reducing blurring 
across different anatomical structures. 
To account for subject-dependent signal fluctuations, a circular region of interest (ROI) 
was drawn in the central part of the crus cerebri of each neuromelanin-sensitive image, 
which was then normalized by the mean signal intensity within this ROI. T1 high signal in 
the SN region was visible in 3 slices, and the middle slice corresponding to the greatest SN 
volume was selected.  
A rectangular region containing the mesencephalon was then selected in this slice, and 
two symmetrical seed points were manually defined on the most medial part of the high-
intensity area in the SN. A region growing algorithm (123) was used for segmentation 
starting from each seed point, and the area of interest (AOI) was automatically drawn. 
Pixels with a signal intensity within the interval Iseed  0.035(Imax-Imin) were labeled as 
belonging to the AOI, where Iseed is the intensity at the seed point, and Imax and Imin the 
maximum and minimum signal intensities within the rectangular mesencephalon ROI. The 
threshold used to delimit the AOI was chosen following a preliminary optimization study 
where the threshold was varied using a batch process with tests performed on several 
example images; the final value of 3.5% was selected as it was the one that provided a 
better visual fit to the anatomical area. The area of interest (AOI) was automatically 
drawn, and the maximal length was then calculated. 
We additionally calculated the global midbrain area and the ratio of SN neuromelanin T1 
high-signal area to total midbrain area (neuromelanin ratio). Images were transferred to a 
PACS system and the slice were the neuromelanin area measurements were made was 
selected; in this slice the midbrain contours were manually drawn and the global area was 





MR imaging of the substantia nigra in PD 
62 
 
2.3. Statistical analysis 
The area, length and SN neuromelanin ratio obtained for each group were compared 
using non parametric analysis. Kruskal-Wallis tests, with pairwise comparisons in which 
the resulting p-values were corrected according to Bonferroni method, and Mann-
Whitney U tests were used as appropriate.  
A p-value of 0.05 was considered significant. Statistical analysis was performed with R 
2.15.2. 
Receiver operation characteristics (ROC) curve analysis was conducted for the comparison 
between PD patients and normal subjects, and the specificity and sensitivity of the tests 
and the optimal cutoff point as well as the area under the curve (AUC) were also 
assessed. 
Differences in the clinical characteristics among these groups were assessed. Differences 
in the sex distribution among groups were evaluated with χ2-test. The Kruskal-Wallis test 
was performed for comparison of the median age between groups as well as for UPDRS 
total score and UPDRS part III. 
 
3. Results 
MR imaging was performed on all subjects, and the image quality allowed the clear 
identification of the high signal area in the SN region (Fig 1). Automated analysis was 
possible on all subjects except one patient in the 2 to 5 year disease duration group 
whose MRI had significant artifacts and had to be excluded. Therefore, 12 patients with 
“de novo” PD, 9 patients with 2 to 5 year disease duration and 10 healthy controls were 
eligible for further analysis. The clinical characteristics of these subjects are shown in 
Table 1. No significant differences were observed in age and sex among the 3 groups, and 
there were also no significant differences in HY stage and UPDRS scores between the 
“de novo” and the 2 to 5 years disease duration PD patients. 
The median area and length obtained for “de novo” PD patients was 19.88 mm2 and 33.41 
mm, respectively. For the 2-5 year PD group, the median area was 12.58 mm2 and the 
median length was 23.14 mm; for healthy controls, an area of 25.40 mm2 and a length of 
52.75 mm were observed. 
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The area and maximal length were markedly decreased in “de novo” and the 2-5 year PD 
groups compared with the healthy control group (Fig 1) with a p-value of 0.003 and a p-
value of 0.002, respectively for area and length in “de novo” patients compared to 
controls and a p-value <0.001 for area and length in the 2-5 year PD group compared to 
controls (Fig 2). However, substantial overlaps were observed between the “de novo” and 
the 2-5 year disease duration groups (Fig 2), with no significant difference observed 
between the two groups (p-value of 0.22 for area and p-value of 0.62 for length), 
although the median area and length of the “de novo” PD group tended to be slightly 
higher than that of the 2-5 year PD group. 
We found no significant differences in the global midbrain area between the three groups 
(p- value > 0.205). The ratio of SN neuromelanin ratio was markedly decreased in the in 
“de novo” and the 2-5 year PD groups compared with the healthy control group (p-value 
of 0.014 and of <0.001, respectively) (Table 2). The ratio also had a substantial overlap 
between the “de novo” and the 2-5 year disease duration groups with no significant 
difference observed between the two groups (p-value of 0.141). 
ROC analyses for the area showed an AUC of 0.73 in patients with “de novo” PD, whereas 
it was 0.85 in patients with 2-5 year disease duration. AUC values obtained for length 
were 0.79 for “de novo” PD and 0.82 for the 2-5 year PD group. 
Among these, the sensitivity and specificity of the SN high signal area for discriminating 
the “de novo” PD group from the healthy control group was 70% and 65%, respectively, 
when the cut-off value for the area was set at 23 mm2. The sensitivity and specificity for 
discriminating the 2-5 year PD group from the control group was 60% and 100%, 
respectively, with an area cut-off value of 21 mm2. The sensitivity and specificity for the 
maximal length of the SN high signal for discriminating the “de novo” PD group from the 
control group was 83.3% and 70%, respectively, for a length cut-off value of 45.73 mm. 
For discriminating the 2-5 year PD group from the control group, the sensitivity and 
specificity was 83% and 70%, respectively, with a length cut-off value of 45.6 mm (Table 3 
and Fig 3). 
 
4. Discussion 
In the present study, with semi-automated MRI measures, we were able to detect 
significant changes in the area and length of the T1-high signal area of the SN 
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corresponding to the neuromelanin in early stage PD compared with healthy individuals. 
Clinical symptoms of PD are generally apparent when a substantial part of the 
dopaminergic neurons of the SN are lost (14,124) and therefore it is expected that even in 
early disease stages, a substantial loss of neuromelanin-containing neurons would be 
detectable by MRI-sensitive sequences. It is also known from pathological studies that the 
neuronal loss in PD is more pronounced in the ventrolateral region of the SNpc with 
relative preservation of the dorsal region (14) and so we studied both the area and length 
of the SN T1-high signal region because the maximal length gives a measure of the 
longitudinal extension additional to the global area. 
In the present study, both the area and the maximal length of the SN T1-high signal 
region were significantly reduced, suggesting neuronal depletion in patients with early PD 
compared with healthy individuals. Moreover, we obtained high sensitivity and specificity 
of the values of both of our measurements when differentiating patients with early PD 
from controls. The sensitivity and specificity of the maximal length are higher that the 
sensitivity and specificity obtained for the area measurements for discriminating the “de 
novo” PD group from the healthy controls. This finding supports the longitudinally 
expected difference of the SN with greater ventrolateral neuronal loss in early stage PD.   
To evaluate the possible impact of midbrain volume reduction in PD patients that might 
influence neuromelanin measurements we calculated the ratio of SN neuromelanin T1 
high-signal area to total midbrain area for each group. As expected the midbrain area was 
similar between the groups and the calculated ratios showed a significant reduction of SN 
neuromelanin in “de novo” and 2-5 year PD patients, demonstrating that the individual 
midbrain area does not influence the detection of neuromelanin changes in PD. 
In our study, we did not observe significant differences in the area or length of the SN 
neuromelanin between the groups with “de novo” and 2-5 year disease duration PD. 
These findings, using semi-automated methods, are consistent with recent findings in a 
study that investigated signal intensity changes in SN neuromelanin (125), which also 
found no difference between untreated and advanced stage (H&Y 3-5) PD patients. 
Interestingly, these findings are also consistent with transcranial sonography studies in PD 
demonstrating that the ultrasound signal does not change in the course of the disease 
(126). We studied the area and length of the SN T1 high signal region, and these measures 
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are similar to the signal intensity changes recently reported in the SNpc (125), providing 
two different measures of the reduction of SN neuromelanin in early PD.  
Our sensitivity and specificity results are consistent with previous reports (125,127). The 
semi-automated method used in our study is less operator dependent and less time 
consuming that the manual SN segmentation for neuromelanin estimation (125). The use 
of a region growing algorithm for SN segmentation increases accuracy and reduces the 
time required for image analysis. To improve signal-to-noise ratio (SNR) of this algorithm 
a previous group performed image smoothing applying a Gaussian filter on a 3D sequence 
(127). As Gaussian filters lead to edge blurring we used an alternative filtering approach 
that gives more accurate area estimations and enabled semi-automated measurements 
of SN T1-high signal on 2D images with only a few required operator dependent steps 
(signal normalization and definition of seed points).  
The correlation of neuromelanin decrease with the known pathological changes 
associated with disease duration and progression of clinical severity (14) needs to be 
investigated. The different imaging and measurement methods in previous studies might 
explain the inconsistent findings in neuromelanin patterns in relation to disease duration 
(63,128). Additionally, the correlation of iron load with the SN neuromelanin-sensitive 
MRI needs further analysis, as it is known that iron content in the SN increases in PD and 
during its progression (129). Neuromelanin exhibits paramagnetic properties when bound 
to iron that result in the acceleration of T1 relaxation (130,131), and therefore, the 
increased iron load in SN in PD patients might enhance neuromelanin-related contrast. 
Variations in the neuromelanin-related signal of the SNpc related to the iron content are 
currently being investigated by our group with a direct correlation of the neuromelanin 
signal with iron quantification with a relaxometry sequence. 
However, our study has several limitations, namely the small number of patients in each 
group and the absence of pathological confirmation because the PD diagnosis was only 
clinical. Another aspect is related to the disadvantages of the imaging technique, 
including the long acquisition time, the relatively low spatial resolution and the existence 
of in-plane signal inhomogeneity. In addition, the region-growing post-processing 
technique used in this study for semi-automated measurement of volumes requires the 
determination of seed points and normalization of signal intensity that could not be 
completely automated. The total imaging analysis is relatively time consuming and 
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requires the implementation of post-processing software that is not widely available. 
However, only two operator-dependent steps are required, and the rest of the analysis is 
automated and operator independent. Motion artifacts were not a problem in our early 
stage patients, with few involuntary movements, but advanced-stage patients might have 
problems that will need to be addressed. 
Further prospective studies are required to address all of these issues.  
 
5. Conclusions 
MR neuromelanin-sensitive images were sufficient for detecting significant changes in the 
SN at the time of clinical diagnosis of PD. Our findings suggest that the neuromelanin 
changes remain stable with disease progression, consistent with previous findings based 
on sonography. MRI neuromelanin-sensitive techniques might become a useful diagnostic 




MR imaging of the substantia nigra in PD 
67 
 
Tables and legends 













63.23(± 11.9) 67.22(±6.7) 61.2(±7.3) 
0.289 
H&Y (mean±SD) 2(2-2) 2(2-2) - - 
Total UPDRS 
(mean±SD) 44.46(±26.0) 





29.08(±14,2) 27.43(±10.4) - 
0.498 
PD: Parkinson’s Disease; No: number; SD: standard deviation. 
 
 
Table 2: SN neuromelanin T1 high-signal and midbrain measurements 
  “de novo” PD 2-5 years PD Controls p-value* 
SN neuromelanin area 
(mm2) – median (range) 
19.88 (4.78-47.84) 12.58 (1.85-28.86) 25.4 (14.51-51.55) <0.001 
SN neuromelanin length 
(mm) – median (range) 
33.41 (7.40-67.89) 23.14 (4.70-63.07) 52.75 (25.53-92.76) <0.001 
Midbrain area (mm2) – 
median (range) 
60.30 (51.88-72.19)  63.20 (56.96-70.42) 59.30 (56.55-66.84) 0.205 
SN neuromelanin ratio – 
median (range) 
0.36 (0.08-0.85) 0.19 (0.03-0.53) 0.42 (0.24-0.83) <0.001 
*Comparisons using Kruskal-Wallis test 




Table 3: ROC analysis of neuromelanin-sensitive MRI for discriminating patients with “de novo” 
PD and 2-5 years PD duration from healthy subjects 
 
 
“de novo" PD vs. control 
 
Cutoff value  Sensitivity (%) Specificity (%) AUC 
Area 23.0mm2 70 65 0.73 
Length 45.8mm 83.3 70 0.79 
 
2 - 5 years PD duration vs. control 
 
Cutoff value  Sensitivity (%) Specificity (%) AUC 
Area 21.1mm2 60 100 0.85 
Length 45.6mm 83 70 0.82 
 
PD: Parkinson’s Disease; AUC: area under the curve 
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Figures and legends 
 
  
Fig. 1. Neuromelanin-sensitive MRI images of the SN of a healthy control (A), a “de novo” PD 
patient (B) and of a 2-5 years PD patient (C) and segmented images of a healthy control (D) and of 
a 2-5 year PD patient (E), showing diminished size of the T1 high intensity area of the SN in PD 




Fig. 2. Areas (A) and maximal length (B) of the SN high intensity region on neuromelanin-sensitive 
MR images in patients with “de novo” and  2-5 year PD and healthy controls p-values, Mann-
Whitney U-test.  
  






Fig. 3. ROC curves of the area for differentiating between “de novo” PD and healthy subjects (A) 
and between 2-5 years PD patients and healthy controls (B); ROC curves of the length to 
differentiate between “de novo” PD and healthy subjects (C) and between 2-5 years PD patients 
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diagnosis of Parkinson’s disease.  
 
Reimão S, Pita Lobo P, Neutel D, Correia Guedes L, Coelho M, Rosa MM, Ferreira J, Abreu 
D, Gonçalves N, Morgado C, Nunes RG, Campos J, Ferreira JJ. 
 
Journal of Parkinson’s Disease – accepted for publication 
  








Quantitative analysis versus visual assessment of neuromelanin MR 
imaging for the diagnosis of Parkinson’s disease 
 
Sofia Reimão1,4, Patrícia Pita Lobo2,4, Dulce Neutel2,4, Leonor Correia Guedes2,4, Miguel Coelho2,4, 
Mario M Rosa2,4, Joana Ferreira3, Daisy Abreu4, Nilza Gonçalves4, Carlos Morgado1, Rita G Nunes3, 
Jorge Campos1, Joaquim J Ferreira4,5* 
 
1 Neurological Imaging Department, Hospital de Santa Maria - Centro Hospitalar Lisboa Norte, Portugal 
2 Neurology Department, Hospital de Santa Maria - Centro Hospitalar Lisboa Norte, Portugal 
3 Instituto de Biofísica e Engenharia Biomédica, Faculdade de Ciências, Universidade de Lisboa, Portugal 
4 Clinical Pharmacology Unit, Instituto de Medicina Molecular, University of Lisbon, Portugal 
5 Laboratory of Clinical Pharmacology and Therapeutics, Faculty of Medicine, University of Lisbon, Portugal 
 
Abstract 
Purpose: Specific MR sequences have been able to identify the loss of neuromelanin in the 
substantia nigra (SN) of early stage Parkinson’s disease (PD) patients. Since this technique may 
have a significant impact in clinical patient management, easy and widely available imaging 
analysis is needed for routine use. In this study we compared a quantitative analysis with a visual 
assessment of SN neuromelanin-sensitive MR images in early stage PD patients, in terms of 
pattern changes recognition and diagnostic accuracy.  
Methods: The inclusion criteria were untreated “de novo” PD patients or a 2 – 5 year PD duration; 
in addition, age matched controls were enrolled. These were studied with a high-resolution T1-
weighted MR imaging sequence at 3.0 Tesla to visualize neuromelanin. The primary outcome was 
the comparison of quantitative width measurement with visual assessment by experienced 
neuroradiologists of SN neuromelanin sensitive MR images for PD diagnosis.   
Results: A total of 12 “de novo” PD patients, 10 PD patients with 2 - 5 year disease duration and 
10 healthy controls were evaluated. We obtained a good accuracy in discriminating early-stage PD 
patients from controls using either a quantitative width measurement of the T1 high signal or a 
simple visual image inspection of the SN region.  
Conclusions: Visual inspection of neuromelanin-sensitive MR images by experienced 
neuroradiologists provides comparable results to quantitative width measurement in the 
detection of early stage PD SN changes and may become a useful tool in clinical practice.  
 
 









Recent MR studies have described a reduction of neuromelanin signal in the substantia 
nigra (SN) of Parkinson’s disease (PD) patients (61,63,132) with high diagnostic accuracy 
even in early disease stages (125,127). These findings reflect the known pathological 
features of PD with dopaminergic neuronal loss in the SN pars compacta and consequent 
reduction of neuromelanin content (9). This neuronal loss occurs asymmetrically and 
primarily in the ventrolateral and caudal region of the SN with relative preservation of the 
dorsal and rostral region (14), and MR-sensitive neuromelanin studies have been able to 
identity these specific disease changes (133). 
PD diagnosis in the early disease stage can be challenging but has important therapeutic 
and prognostic consequences (18). For this reason, neuromelanine sensitive-MR imaging 
may have the potential to become an alternative to the more expensive and risky nuclear 
medicine techniques (134) currently used in the diagnostic evaluation of early stage PD. 
Previous neuromelanin MR studies have used automated post-processing (127) or manual 
ROI tracing of the SN region (125,133) but these methods are time consuming or need 
additional post-processing software. Since this technique may have a significant impact 
on clinical patient management, an easy and widely available mechanism for image 
analysis is needed to enable the routine use of these MR images.   
In this study we examined neuromelanin-sensitive MR imaging in “de novo” untreated PD 
patients and in PD patients with a 2 – 5 year disease duration, comparing quantitative 
width measurement with visual image assessment by experienced neuroradiologists to 
ascertain their ability to detect SN neuromelanin changes and to differentiate between 
PD early-stage patients and controls. 
To the best of our knowledge this is the first study in early stage PD patients comparing 
different neuromelanin MR imaging evaluation methods, in particular using visual 
assessment or manual width measurements. 
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2. Patients and methods 
 
2.1. Patients and control subjects  
The study was a cross-sectional case-control (prospective follow-up ongoing) that 
included 32 subjects: 12 “de novo” patients with PD, 10 PD patients with 2 - 5 year 
disease duration and 10 healthy subjects. Patients were recruited from the Movement 
Disorders Unit of the University Hospital of Santa Maria-Lisbon.  “De novo” PD patients 
were included at the time of clinical diagnosis if they were not on antiparkinson 
medications. PD patients with 2 - 5 year disease duration were receiving optimal 
pharmacotherapy with levodopa or dopamine agonists. All patients were diagnosed with 
PD by a movement disorders specialist according to the UK Brain Bank criteria (19) and 
were rated using the Unified Parkinson’s Disease Rating Scale (UPDRS). The healthy 
control subjects were recruited from local hospital staff and relatives. Dementia, 
psychiatric illness or contraindications to an MRI were the exclusion criteria. 
All the examinations were performed with the understanding and written consent of each 
subject, with approval from the local ethics committee, and in compliance with national 
legislation and Declaration of Helsinki guidelines. 
 
2.2. MRI protocol 
2.2.1. Imaging protocol 
All data were acquired with a 3.0-Tesla Phillips scanner (Phillips Achieva). The following 
pulse sequence was used as previously described by Sasaki and colleagues (61): T1-
weighted FSE: repetition time/effective echo time, 633/10ms; echo train length, 3; 
number of slices, 20; slice thickness, 2.5 mm; intersection gaps, 0 mm; matrix size, 548 x 
474; field of view, 220x220 mm2 (pixel size: .40 x .40 mm2); and acquisition time of 8 min. 
The sections were carefully set in the oblique axial plane perpendicular to the fourth 
ventricle floor with coverage from the posterior commissure to the inferior border of the 
pons.  
Additionally, T1- and T2-weighted images of the entire brain were obtained in all subjects 
and evaluated by an experienced neuroradiologist to exclude other pathological imaging 
findings that could interfere with further assessment. 
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2.2.2. Imaging analysis  
Images were transferred to a PACS workstation for analysis. T1 high signal in the SN 
region was visible in 3 slices, and the middle slice corresponding to the greatest SN 
volume was selected. In this slice, a line was defined following the maximal longitudinal 
length of the SN area and was divided into three equal segments to define the lateral, 
central and medial SN parts. One of the authors (a neuroradiologist), blinded to the 
subject information, performed manual measurements of the maximal width of the T1 
high signal area perpendicular to the length line for the three SN parts, as shown in Fig 
1d. Measurements were performed on both sides. 
In addition, visual assessment of the neuromelanin SN T1 high signal was performed by 
two neuroradiologists (R.S. and M.C.) who have more than 10 years experience, were 
blinded to the clinical status of the subjects and did not know each other’s evaluation nor 
the results of the width measurements. SN T1 high signal area was visible on three slices 
and the middle slice was selected for analysis, similar to the quantitative method. The SN 
T1 signal was then evaluated according to symmetry and size/signal intensity (rated as 
normal/reduced). Where applicable, the SN part of T1 high signal greatest size/signal 
intensity reduction was identified (medial/central/lateral). According to these parameters 
the subjects were then classified into 4 groups: “probable PD”, if the SN T1 high signal 
area was markedly reduced in size/intensity and markedly asymmetrical; “possible PD” 
was used for reduced size/signal intensity and asymmetrical T1 high signal SN areas and 
“not PD” if the SN T1 high signal area was normal in size/intensity and symmetrical. All 
other cases were rated “uncertain”. 
 
4.3. Statistical analysis 
The SN T1 high signal width obtained for each group was compared using non parametric 
analysis. Kruskal-Wallis tests, with pairwise comparisons in which the resulting p-values 
were corrected according to Bonferroni method, and Mann-Whitney U tests were used as 
appropriate. Receiver operation characteristics (ROC) curve analysis was conducted for 
the comparison between PD patients groups and normal subjects, and the specificity and 
sensitivity of the tests and the optimal cutoff points as well as the area under the curve 
(AUC) were also assessed. Differences in the sex distribution among groups were 
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evaluated with χ2-test. The Kruskal-Wallis test was performed for comparison of the 
median age between groups as well as for UPDRS total score and UPDRS part III. 




MR imaging quality allowed the identification of the SN high signal area and width 
measurements on all subjects. We analyzed 12 patients with “de novo” PD, 10 patients 
with 2 - 5 year disease duration and 10 healthy controls whose clinical characteristics are 
shown in Table 1. No significant differences were observed in age and sex among the 3 
groups, and there were also no significant differences in HY stage and UPDRS scores 
between the “de novo” and 2 - 5 years disease duration PD patients. All PD patients had 
mild disease severity with H & Y of 1-2 and mean UPDRS motor score of 29.12(±12.92). 
Symptoms at onset were predominantly unilateral with half of the “de novo” PD patients 
presenting criteria for asymmetric disease on UPDRS part III (135). 
Quantitative width measurements of SN T1 high signal are shown on Table 2. The median 
global averaged width of the T1 high signal in the SN was significantly decreased in both 
PD groups when compared with healthy controls with a p-value <0.001 and 0.002 
respectively (Fig 2). This pattern of width differences between the groups was more 
pronounced in the lateral, rather than the central, SN segments (Table 2 and Fig 2) and 
the medial SN width was only decreased significantly when comparing the 2-5 year PD 
group with the controls (p-value=0.002). We found no significant differences between left 
and right SN width for all the segments (p-value = 0.714). A substantial overlap was 
observed between the “de novo” and the 2-5 year PD groups, with no significant 
differences in the width measurements. 
ROC analysis is detailed in Table 3 and indicated good area under the curve (AUC) values 
for the lateral segment width in both PD patients groups. The sensitivity and specificity of 
the width measurement in the lateral part of the SN was 88% and 65% respectively, when 
the cut-off value for SN width was set at 1.86mm for discriminating the “de novo” PD 
group vs. controls and were both 75%, with a width cut-off value of 1.97mm, for 
discriminating between the 2-5 year PD group and controls (Table 3). 
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The visual assessment results of the SN high signal area for the two raters are shown in 
Table 3. The neuromelanin size/signal was decreased in the vast majority of PD patients 
(only rated as normal in 2 PD “de novo” patients). Marked asymmetry was found in 
almost all the 2-5 year PD patient’s but only in half of the “de novo” PD group. Raters 
independently classified as “probable/possible PD” 17/22 of PD patients (rater 1) and 
20/22 (rater 2); 6/10 and 8/10 of the controls were rated as “not PD”. No PD patient was 
classified as “not PD” and no healthy control was classified as “probable PD”. 
 
6. Discussion 
Visual assessment of neuromelanin-sensitive MR images by experienced 
neuroradiologists was able to detect changes in the SN of early-stage PD patients with a 
discrimination power similar to that of a quantitative measurement of T1 high signal 
width. The sensitivity, specificity and AUC of the SN neuromelanin width measurements 
for the distinction of early stage PD patients from healthy controls were comparable to 
the PD patient’s identification rates obtained by visual assessment. 
Neuroradiologists were also able to detect a greater reduction of neuromelanin in the 
lateral part of the SN in PD patients and a less pronounced change in the central and 
medial segments, in accordance with the quantitative width measurements and reflecting 
the known pathological gradient of neuronal depletion in PD (11).  
Although the quantitative width measurements were not significantly different between 
the “de novo” and the 2-5 year PD groups, on visual inspection the 2-5 year PD patients 
were classified with greater certainty as “probable PD” that the “de novo” PD patients. 
We think that these findings may reflect the more global analysis provided by visual 
inspection as it takes into account several parameters such as size, signal and 
morphological data, allowing the identification of a disease pattern. These data are in 
agreement with neuropathology findings in PD which correlate the decrease of SN 
neuromelanin with clinical severity (14). However this decrease was not reflected in our 
quantitative measurements which were similar to previous reports of SN neuromelanin 
signal intensity changes (125) and transcranial sonography (126) in PD suggesting a 
stability of the neuromelanin content with disease duration. The different imaging and 
post-processing methods used in these studies may explain the inconsistent findings in 
MR imaging of the substantia nigra in PD 
80 
 
neuromelanin patterns with disease duration (63,128) and additional research on 
neuromelanin MRI signal changes throughout PD evolution is needed. 
PD motor symptoms are usually asymmetric at the time of clinical presentation and 
throughout the course of the disease (19,135,136). We were not able to find a significant 
asymmetry in the SN neuromelanin nor a correlation with the clinically most affected side 
in our PD patients either with visual inspection or with quantitative analysis. This may be 
due to the small number of subjects in our samples which limits the power of the study.  
Previous neuromelanin MR studies have used quantitative measurements with 
automated analysis or manual ROI tracing (125,127,133). These post-processing 
techniques are time consuming or need post-processing software which limits clinical 
implementation of neuromelanin imaging. In our study, visual inspection was able to 
identify a pattern of SN neuromelanin that allowed a good discrimination between PD 
patients and controls with high agreement with quantitative measurements. Additionally, 
the sensitivity and specificity obtained for these MRI neuromelanin studies are only 
slightly lower than those obtained in 123I- FP-CIT SPECT studies in identifying PD patients 
(134,137). Finally, neuromelanin sensitive MRI has a relatively low cost compared with 
PET or SPECT imaging and can be applied to all compliant patients with few involuntary 
movements and no MRI contraindications, unlike transcranial sonography where up to 
18% of individuals have insufficient temporal acoustic windows (138).  
Our study has several limitations, mainly the small number of patients. The imaging 
technique requires a 3.0Tesla MR machine which has an impact on availability and the 
neuromelanin sequence has a long acquisition time, a relatively low spatial resolution and 
is prone to in-plane signal inhomogeneity. In addition, we used a fully manual, operator 
dependent image analysis technique that can have a high variability. 
However, we obtained a good agreement in visual assessment between the two raters 
and the findings are consistent with quantitative data and with previous studies using 
different methods and techniques (63,125,127). 
Motion artifacts were not a problem for visual inspection or width measurement in our 
PD patients groups, but these were early stage HY 1-2, with few involuntary 
movements. Image artifacts may be an issue in advanced-stage PD patients interfering 
with image evaluation.  
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Using a fast, easy, highly available assessment of SN neuromelanin with visual inspection 
or width measurement, we were able to detect a disease pattern change in early stage PD 
patients. Visual inspection of MR sensitive neuromelanin imaging of the SN may become 
an attractive tool in clinical practice for PD diagnosis, but additional studies are needed to 
validate this method and to determine how this imaging technique can affect the 
management of PD patients. 
 
5. Conclusion 
Visual inspection of neuromelanin-sensitive MRI techniques has similar results compared 
to a quantitative width analysis of SN changes in early-stage PD, allowing the 
identification of a specific disease pattern and a good distinction of PD patient’s from 
healthy controls. These findings can have an impact on a wider use of neuromelanin MR 
imaging in clinical practice for PD patients evaluation. 
 
  

















63.23(± 11.9) 66.9(±6.4) 61.2(±7.3) 
0.289 
H&Y (mean±SD) 2(2-2) 2(2-2) - - 
Total UPDRS 
(mean±SD) 44.46(±26.0) 





29.08(±14.2) 25.88(±11.3) - 
0.498 




Table 2: SN neuromelanin T1 high-signal width measurements 
  “de novo” PD 2-5 years PD Controls p-value* 
SN global average width 
(mm) – median (range) 
2.48 (0 - 0.539) 2.32 (0 - 4.33) 3.25 (0 - 0.597) <0.002 
SN lateral width (mm) – 
median (range) 
1.54 (0 - 0.264) 1.24 (0 - 0.387) 2.25 (0 - 0.399) <0.002 
SN central width (mm) – 
median (range) 
2.60 (0.138 - 0.457)  2.32 (0.000 - 0.417) 3.34 (0.231 - 0.536) 0.019 
SN medial width (mm) – 
median (range) 
3.39 (0.214 - 0.539) 3.30 (0.163 - 0.433) 3.91 (0.307 - 0.597) 0.005 
*Comparisons using Kruskal-Wallis test 
PD: Parkinson’s Disease 
 
  




Table 3: Visual assessment of the SN T1 high signal 
 
 Rater 1 Rater 2 
SN T1 high signal area Subject’s 
classification 
























6/6 5 probable PD 
3 possible PD 
4 uncertain 
0 not PD 




11/1 6 probable PD 
4 possible PD 
2 uncertain 
0 not PD 




8/2 9 probable PD 
1 possible PD 
0 uncertain 
0 not PD 




10/0 10 probable PD 
0 possible PD 
0 uncertain 
0 not PD 




2/8 0 probable PD 
4 possible PD 
0 uncertain 
6 not PD 




3/7 0 probable PD 
0 possible PD 
2 uncertain 
8 not PD 
PD: Parkinson’s disease; : reduced; A/S: asymmetric/symmetric 
 
Table 4: ROC analysis of neuromelanin signal width for discriminating patients with “de novo” PD 
and 2-5 year PD duration from controls. 
 
“de novo" PD vs. controls 
 
Cutoff value  Sensitivity (%) Specificity (%) AUC 
SN lateral part 0.1860000 88,5 65 0,806 
SN central 0.3130000 69,2 85 0,748 
SN medial part 0.3370000 30,8 100 0,652 
 
2 - 5 years PD vs. controls 
 
Cutoff value  Sensitivity (%) Specificity (%) AUC 
SN lateral part 0.1970000 75 75 0,77 
SN central 0.3130000 65 85 0,739 
SN medial part 0.3670000 55 95 0,792 






Fig 1. SN neuromelanin-MRI of a “de novo” PD patient (a), a 2-5 year PD patient (b) and a control 
subject (c); width measurement example (d) in a control subject.  
 
 
Fig 2. Width of the SN high-intensity region on neuromelanin-sensitive MR images in patients with 
“de novo” PD, 2-5 year PD and healthy controls; Mann-Whitney U-test. 
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Background: Magnetic resonance studies have demonstrated a significant reduction of 
neuromelanin in the substantia nigra (SN) of Parkinson’s disease (PD) patients with high accuracy 
for differential diagnosis compared to non-PD controls and Essential Tremor. However, studies 
state not knowing how paramagnetic effects of iron influence neuromelanin signal as a limitation. 
In this study we combined a neuromelanin-sensitive MR sequence with T2*-relaxometry iron 
quantification analysis to study the SN of early-stage PD patients to investigate the correlation 
between these parameters. 
Methods: The inclusion criteria were untreated “de novo” PD patients and a 2 – 5 year disease 
duration (early PD); in addition, age matched controls were enrolled. These were studied at 3.0 
Tesla with a high-resolution T1-weighted MR sequence to visualize neuromelanin and a 
relaxometry sequence for iron quantification. The primary outcome was the correlation of the 
width of the neuromelanin high signal region and the T2* values in the lateral, central and medial 
segments of the SN.  
Results: We found very weak correlations of T2* values with neuromelanin width, positive for 
global and negative for the medial and lateral SN segments in both PD groups and control 
subjects. The SN neuromelanin width was markedly reduced in the “de novo” and early PD groups 
compared with controls in all SN segments, but no significant difference in T2* values was found 
between the groups.  
Conclusions: SN neuromelanin signal does not have a significant correlation with iron content in 
PD patients or controls. The neuromelanin MR signal reduction in PD does not seem to be 
significantly influenced by paramagnetic iron effects. 








1. Introduction  
Recent magnetic resonance (MR) studies have described a reduction of neuromelanin in 
the substantia nigra (SN) and locus coeruleus (LC) of Parkinson’s disease (PD) patients (61-
63,125,139), with a very high diagnostic sensitivity and specificity for disease diagnosis 
even in early disease stages (125,139). These in vivo MR imaging findings seem to 
reproduce the known pathological pattern of greater pigmentation loss in the lateral SN 
of PD patients (125) and so this imaging technique may become a valuable tool for 
disease investigation.  
However, all previously published MR neuromelanin studies refer not being able to 
ascertain how the local iron content in the SN could influence the neuromelanin-sensitive 
MR signal changes in PD as a significant limitation (62,63). 
It is known that iron content in the SN is increased in PD at the time of diagnosis and 
seems to increase with disease progression (69,70,129). Dopaminergic neurons of the SN 
pars compacta (SNpc) and noradrenergic neurons of the LC contain significant amounts of 
iron sequestered in neuromelanin granules (65) with approximately 20% of SN iron 
bonded to neuromelanin in its ferric form (66) and the remainder stored as ferritin and 
hemosiderin (67,68).  
In PD, as evidenced by post mortem studies, individual neuromelanin granules of the SN 
have higher iron levels (71), but the loss of functional nigral neurons early in the course of 
the disease results in a general decrease in the number of neuromelanin granules, with 
iron being sequestered in SNpc neurons Lewy bodies (72) and an increased loading of 
ferritin with iron (73).  
Paramagnetic substances such as iron increase proton transverse relaxation rate (R2), but 
the MR signal changes are dependent on several factors (74) that result from tissue 
composition with multiple interactions (75). Different MR imaging sequences have been 
used to study iron distribution in PD, yielding inconsistent results but recent studies 
report a difference in magnetic susceptibility (82) and R2* values in the lateral SN of PD 
patients (80). However, the influence of iron paramagnetic effects on T1-weighted 
neuromelanin-sensitive MR signal changes in PD patients is unknown.  
To investigate the correlation and the possible contribution of the iron content in the 
different segments of the SN to the neuromelanin signal changes in PD, we combined a 
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specific neuromelanin-sensitive MR sequence with an iron quantification analysis using 
T2*-relaxometry at 3.0T to study early-stage PD patients. To the best of our knowledge 
this is the first MR study analyzing the correlation of SN neuromelanin and iron in PD. 
 
2. Patients and methods 
2.1. Patients and control subjects  
The study was a cross-sectional case-control (prospective follow-up ongoing) that 
included 32 subjects: 12 “de novo” patients with PD, 10 PD patients with a 2 - 5 year 
disease duration (early PD) and 10 healthy subjects. Patients were recruited from the 
Movement Disorders Unit of the University Hospital of Santa Maria-Lisbon.  “De novo” PD 
patients were included at the time of clinical diagnosis if they were not on antiparkinson 
medications. PD patients with 2 - 5 year disease duration were receiving optimal 
pharmacotherapy with levodopa or dopamine agonists. All patients were diagnosed with 
PD by a movement disorders specialist according to the UK Brain Bank criteria (19) and 
were rated using the Unified Parkinson’s Disease Rating Scale (UPDRS). “De novo PD” 
patients were drug naïve and early PD patients were imaged and clinically evaluated on-
medication. The healthy control subjects were recruited from local hospital staff and 
relatives. Dementia, psychiatric illness or contraindications to an MRI were the exclusion 
criteria. 
All the examinations were performed with the understanding and written consent of each 
subject, with approval from the local ethics committee, and in compliance with national 
legislation and Declaration of Helsinki guidelines. 
 
2.2. MRI protocol 
2.2.1. Imaging protocol 
A combined neuromelanin and iron quantification MR protocol was performed 
simultaneously in a 3.0-Tesla Phillips scanner (Philips Achieva; Philips Medical Systems, 
Best, Netherlands). The neuromelanin-sensitive pulse sequence parameters were similar 
to the previously described by Sasaki and colleagues (61): T1-weighted FSE: repetition 
time/effective echo time, 633/10 ms; echo train length, 3; number of slices, 20; slice 
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thickness, 2.5 mm; intersection gaps, 0 mm; matrix size, 548 x 474; field of view, 220 x 
190 mm2 (pixel size: .40 x .40 mm2); and acquisition time, 8 min). The intersection gap 
was set to 0 mm and not to 1mm as in previous studies (61) to ensure full coverage of the 
SN; to avoid cross-talk effects related to overlapping slice profiles, an interleave slice 
order was used, maximizing the time between excitation of adjacent slices. The sections 
were carefully set in the oblique axial plane perpendicular to the fourth ventricle floor 
with coverage from the posterior commissure to the inferior border of the pons.  
The T2* relaxation data were acquired with a multiecho FFE sequence with 7 equally 
spaced echoes with a spacing of 4.7 ms, starting from 13.8 ms; repetition time 1406 ms, 
flip angle 18°; 28 slices; slice thickness 4mm, gaps, 1mm; matrix size, 288 x 160, field of 
view, 240 x 180 mm2; and acquisition time 4 min. Images were acquired in axial 
orientation parallel to the commissures line and covering the whole brain. 
In addition, T1- and T2-weighted images of the entire brain were obtained in all subjects 
and evaluated by an experienced neuroradiologist to exclude other pathological imaging 
findings, namely, changes in the parkinsonian index and other atypical parkinsonian 
syndrome changes, and lesions in the SN area that could interfere with further 
assessment. 
 
2.2.2. Imaging analysis  
Images were transferred to a PACS workstation for analysis, which was performed blinded 
to patient’s diagnosis.  
T1 high signal in the SN region was visible in 3 slices, and the middle slice, corresponding 
to the greatest SN volume, was selected. In this slice, a line was defined following the 
maximal longitudinal length of the SN area and was divided into three equal segments 
defining the lateral, central and medial SN parts. One of the authors (a neuroradiologist), 
blinded to the subject information, performed manual measurements of the maximal 
width of the T1 high signal area perpendicular to the length line for the three SN parts (Fig 
1 A), as previously reported (139). Measurements were performed on both sides. 
T2* maps (T2* = 1/R2*) were calculated using an in-house tool developed in Matlab 
(version 7.11; The Mathworks, Natick, MA, USA) blinded to the neuromelanin 
measurements. Prior to fitting, the logarithm of the signal in each voxel was calculated. A 
voxel-by-voxel linear least squares fitting of the log-signal ln[𝑆(𝑇𝐸)] was performed using 
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the data for all 7 echo-times as described by the equation, where S0 would be the signal 
measured at zero TE: 




To minimize the impact of potential image outliers, the Matlab robustfit function was 
used to perform linear regression while automatically adjusting the weighting factor given 
to each time point (140).  
Regions of interest (ROIs) were manually drawn for each individual in the FFE image 
corresponding to the shortest TE, blinded to the neuromelanin measurements. The slice 
immediately inferior to the red nucleus was selected, corresponding to the greatest SN 
volume. The maximal longitudinal length of the SN area was divided in three equal 
segments defining SN lateral, central and medial parts, similar to the neuromelanin 
measurements. We then drew ROIs in the center of each SN segment, with no overlap 
(Fig 1 B and C) with an equal diameter (each with four voxels - voxel size 0.43mm - 
providing an ROI area of 2.3mm2). ROIs were drawn bilaterally and the mean T2* values 
were extracted.  The mean value across the left and right ROIs in the SN was used for 
statistical analysis. 
 
6.3. Statistical analysis 
Differences in the clinical characteristics among these groups were assessed using χ2-test 
and Kruskal-Wallis test. For each SN ROI we assessed neuromelanin and T2* differences 
between groups using non parametric analysis. For Kruskal-Wallis tests, with pairwise 
comparisons, the resulting p-values were corrected according to the Bonferroni method.  
Spearman correlation was assessed for each SN segment between neuromelanin width 
and the T2* quantitative value. 
A p-value of 0.05 was considered significant. Statistical analysis was performed with R 
2.15.2 (R Foundation for Statistical Computing, Vienna, Austria). 
 
7. Results 
The identification of the SN neuromelanin high signal area and the acquisition of T2* 
maps was feasible in all subjects. We analyzed 12 patients with “de novo” PD, 10 early PD 
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patients with 2 - 5 year disease duration and 10 healthy controls whose clinical 
characteristics are shown in Table 1. No significant differences were observed in age and 
sex among the 3 groups, and there were also no significant differences in HY stage and 
UPDRS scores between the “de novo” and the early PD patients. Symptoms at onset were 
predominantly unilateral with half of the patients presenting criteria for asymmetric 
disease on UPDRS part III (141). 
To study the correlation of the neuromelanin width measurements with the T2* values 
we analyzed the SN globally, with an average of the measures of the 3 segments, and 
then considered the different segments separately. For the global SN we found only a 
very weak positive correlation of T2* values with the neuromelanin width (value of 0.15) 
(Table 2). For the different SN segments analyzed separately, in the medial and lateral SN 
segment we found a negative correlation of these measurements for all groups; in the 
central area a negative correlation was found only for the early PD group (Table 2). 
Combining both PD groups and analyzing them as a whole, the correlation value was 0.25, 
positive but very weak (p-value 0.004) regardless of the SN position. We found a weak 
correlation between the measured parameters with regards to sides (right and left) for 
each group [early PD : 0.205 (p-value: 0.414), “de novo” PD: 0.12 (p-value: 0.609), Control 
group: -0.014 (p-value: 0.94)]. 
The SN neuromelanin manual width measurements were markedly reduced in the “de 
novo” and early PD groups compared with controls in all SN segments with p-values 
<0.001 (Table 2). The greatest reduction was evident at the lateral and central SN 
segments with p-values of <0.001 and 0.005, respectively. There was no significant 
difference between “de novo” and early PD groups for the neuromelanin measurements 
on all the segments (Table 3), although the values of the former were slightly lower than 
the latter. No significant differences were found in neuromelanin measurements between 
right and left sides for either group (p-value for controls of 0.53, p-value for early PD 
patients of 0.782 and p-value for “de novo” patients of 0.631). 
We found no statistically significant difference in T2* values between the “de novo” PD, 
early PD and control groups in either of the SN segments (p-values of 0.16, 0.52 and 0.88 
for the medial, lateral and central SN, respectively) (Table 4), although the median T2* 
values were lower in both PD patients groups than in the control group. 
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For each group there were significant differences between the T2* values between the 
three SN segments (p-value of 0.01 for the Controls, a p-value of 0.01for the early PD 
group and a p-value of 0.001 for “de novo” PD patients group) (Table 4), with lower 
values in the medial segment and higher in the lateral. For the three groups significant 
differences were found between the lateral and medial segment, and for the “de novo” 
group there were also significant differences between central and medial segment. 
No significant differences were found between the right and the left side T2* 
measurements either globally (p-value of 0.78) or with respect to group (controls p-value 
= 0.88, “de novo” PD p-value = 0.63 and early PD p-value = 0.78). 
 
4. Discussion 
The combined analysis of the SN neuromelanin and T2* values did not find a significant 
correlation between the two parameters. There was only a very weak correlation 
between T2* values and neuromelanin width with a positive value for the global 
measurements and a negative value for the medial and lateral segments. 
Neuromelanin is thought to protect neurons from oxidative stress mediated by free 
metals or free radicals (35,142,143), sequestering iron in the SN and LC neurons (144). 
However the reduction of nigral neurons in the early stage of PD diminishes the number 
of neuromelanin granules with a consequent reduction of regional iron load of the 
granules. We hypothesize that this reduction in the percentage of iron that is stored 
bound to neuromelanin with a possible increase of the proportion of iron stored as 
ferritin, hemosiderin and in Lewy bodies might explain the very low and even absence of 
correlation we found between neuromelanin measurements and iron levels in the SN of 
early stage PD patients. Another possibility is that these parameters reflect different 
pathophysiological processes with separate mechanisms involved in SN neuronal 
neuromelanin loss compared to the causes of increased iron accumulation. The 
significance of the different associations (positive/negative) among groups and SN 
segments (Table 2) is hard to interpret due to the limited number of patients and the 
weak correlation values; future studies are needed to clarify these data. 
As expected the SN neuromelanin was significantly decreased in our early stage PD 
patients groups compared to controls, in agreement with previous studies using different 
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imaging analysis methods (61-63,125). We used manual width measurements of the SN 
T1 high signal region to study the pattern changes in its different segments and were able 
to detect a greater lateral reduction of neuromelanin signal, as expected (61,125,140). 
However, we found no significant differences in the SN T2* measurements of PD patients 
compared to controls, although the values of the controls tend to be higher than the PD 
groups for all the segments. 
The T2* values of the medial SN are lower than the central or the lateral segments for all 
groups, which reproduces the expected rostral-caudal gradient in susceptibility in PD 
patients and controls (82). 
These MR relaxometry findings do not reproduce the results of some of the previous MR 
studies using R2* or SWI which reported differences in the lateral (but not medial) SN of 
PD patients suggesting a relative increase of iron (82,80). The very early disease stages of 
our patients or the small sample size limits the power of our findings. However, in the 
literature there is a wide variability of results regarding iron MR changes in PD 
(121,145,146), possibly due to methodology differences in the estimation of brain iron, 
the anatomical variability or the individual variations of the SN size and shape, the 
evaluated disease stages and lack of reproducibility studies, yielding inconsistent results. 
In brain tissue multiple iron interactions occur, possibly explaining the poor correlation 
between T2 times and direct measures of iron and ferritin, with factors other than iron 
having a role in determining the transverse relaxation parameters (75,147). Shortened T2 
values in the SN and striatum have been reported in PD, but with small changes, 
apparently unrelated to disease duration, and with a substantial overlap between 
patients and controls (148,149). T2* imaging methods have shown a correlation between 
increased SN iron-related contrast and clinical severity (150), and T2’ an increased iron 
content in the SN (129) that correlated with motor features (151). We used a quantitative 
T2*-relaxometry to measure brain iron because this appears to be the most sensitive 
parameter to study iron concentration in vivo (78).  
Previous studies in healthy subjects found no significant changes in the SN iron content 
with increasing age (147) and in our study there was no significant age differences 
between PD patients and healthy controls; so the obtained T2* values do not seem to be 
influenced by the age interval of the studied subjects. 
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In spite of the clinical asymmetrical presentation in most of our PD patients, we found no 
significant differences between the left and the right SN neuromelanin or T2* values. 
Previous studies of chemical analysis in healthy subjects found higher iron concentrations 
on the left hemisphere compared to the right which was thought to be related to motor 
lateralization and location of dopaminergic neurons (152). However, these data were not 
reproducible in a posterior study that found no parallel hemispheric differences in the 
relaxation rates (78), similar to our findings in PD and control subjects. 
“De novo” PD patients have high UPDRS part III scores, but contrary to the early PD 
group, they were evaluated before medication was initiated, and the values have a wide 
range (15-64 years) at the expense of the high value of 3 patients that had a wide interval 
from the beginning of symptoms until PD diagnosis.   
Our study has several limitations, namely the small number of patients in each group and 
the absence of pathological confirmation. Further complications are due to disadvantages 
of the imaging technique, including the long acquisition time of the neuromelanin-
sensitive sequence with additional relatively low spatial resolution and in-plane signal 
inhomogeneity. However, we used a fully manual, operator dependent image analysis, 
that did not need post-processing software which makes it a widely available method. 
Our manual approach has the additional advantage of identifying individual variations of 
SN size and shape, significantly improving anatomical precision in width measurements 
and ROI placement. On the other hand, due to wider areas of SN in the selected slice, the 
sub-thalamic nucleus may not have been completely excluded from the ROIs. 
Motion artifacts were not a problem for neuromelanin width measurement or the 
elaboration of T2* maps in either of our PD patients groups, but these were early stage 
HY 1-2, with few involuntary movements. Image artifact may be an issue in advanced-
stage PD patients and will need to be addressed.  
The within-subject and inter-rater reproducibility of these measurements has not been 
fully established, further studies are required to address this issue and allow a wider 
implementation of this multimodal MR imaging analysis. 
 
  




The iron content in the SN of early stage PD patients does not have a significant 
correlation with neuromelanin MR signal changes. The SN signal changes in PD patients 
can be attributed to a pigment reduction and are not directly related to local iron 
concentration. Iron accumulation and neuromelanin reduction in PD may be independent 
processes whose contribution to PD pathophysiology needs to be studied.   
 
Tables and legends 
 
Table 1: Demographics for Parkinson’s disease patients and control subjects 
 
  “de novo” PD Early PD Controls p-value 
No. 
(female/male) 




63.2(± 11.9) 66.9(±6.4) 61.2(±7.3) 
0.28 
H&Y (mean±SD) 2(2-2) 2(2-2) - - 
Total UPDRS 
(mean±SD) 44.4(±26.0) 




29.0(±14.2) 25.8(±11.3) - 
0.49 





Table 2: Spearman Correlation between SN T2* and neuromelanin width 
 
 
Spearman Correlation between SN T2*and neuromelanin width (p-value) 
 
Regardless position Considering position 
  
SN lateral SN medial SN central 
Total 0.248 (0.001) NA NA NA 
“de novo” PD 0.317 (0.013) -0.024 (0.917) -0.085 (0.719) 0.054 (0.821) 
Early PD -0.002 (0.989) -0.104 (0.699) -0.436 (0.091) -0.557 (0.024) 
Controls 0.304 (0.025) -0.203(0.418) -0.082(0.1578) 0.260(0.297) 
SN: substantia nigra; PD: Parkinson’s disease; NA: Not applicable 
 
  




Table 3: SN neuromelanin T1 high-signal width measurements 
*Comparisons using Kruskal-Wallis test 
PD: Parkinson’s Disease; SN: substantia nigra 
 
  
Table 4: T2* values in the SN segments 
 
T2* (sec) (Median ±range) 
  Controls Early PD “de novo” PD p-value between groups 
SN global 25.35 (12.5-53.8) 21.05 (9.8-48.2) 21.05 (10.5-41.5) 0.11 
SN lateral 29 (20.2-42.9) 27.15 (9.8- 45.6) 25.7 (13.7-41.1) 0.52 
SN central 24.9 (16.7-42.2) 23.65 (10-48.2) 26.35 (10.5-41.5) 0.88 
SN medial 19.9 (12.5-53.8) 18.7 (10.8 -28.7) 17.1 (12 -31.8) 0.16 
p-value between segments 0.01 0.01 0.001 
 
Comparisons using Kruskal-Wallis test 
PD: Parkinson’s Disease 
 
 




Fig.1. Analysis of the SN neuromelanin and FFE MR imaging. Neuromelanin width measurements 
in the SN segments in a healthy control (A); MR FFE image with the shortest TE with drawn ROIs in 
the medial, central and lateral SN segments (B) and corresponding T2* map (C). 
 
 
  “de novo” PD Early PD Controls p-value* 
SN global average width (mm) – 
median (range) 
2.48 (0 – 5.39) 2.32 (0 - 4.33) 3.25 (0 – 5.97) <0.002 
SN lateral width (mm) – median 
(range) 
1.54 (0 – 2.64) 1.24 (0 – 3.87) 2.25 (0 – 3.99) <0.002 
SN central width (mm) – median 
(range) 
2.60 (1.38 – 4.57)  2.32 (0 – 4.17) 3.34 (2.31 – 5.36) 0.019 
SN medial width (mm) – median 
(range) 
3.39 (2.14 – 5.39) 3.30 (1.63 – 4.33) 3.91 (3.07 – 5.97) 0.005 












2.4. Reproducibility of diffusion tensor imaging (measurements) in early stage 
Parkinson’s disease 
Reimão S, Morgado A, Nunes RG, Pita Lobo P, Neutel D, Abreu D, Gonçalves N, Campos J, 
Ferreira JJ.  
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Purpose: Recent diffusion tensor imaging (DTI) studies have suggested that microstructural 
abnormalities in the substantia nigra (SN) of early stage Parkinson’s disease (PD) patients may 
emerge as a possible diagnostic biomarker. We sought to establish the reproducibility of DTI 
measurements in early stage PD patients as well as in controls, since several factors can increase 
signal variability of diffusion-weighted images influencing DTI metrics in the SN.  
Material and Methods: The inclusion criteria were untreated “de novo” PD or a 2 – 5 year disease 
duration; age matched healthy controls were also enrolled. These were studied with a DTI 
sequence at 3 Tesla with 3 acquisitions: a baseline scan, a repetition within the same session and 
a third acquisition 15 days later. Reproducibility of fractional anisotropy (FA) and mean diffusivity 
(MD) were assessed using a region-of-interest (ROI)-based approach in the SN and quantified 
using the intraclass correlation coefficient (ICC).  
Results: A total of 7 “de novo” PD patients, 7 PD patients with a 2 – 5 year disease duration and 6 
controls were evaluated. We obtained high ICCs indicating a good level of reliability for all 
diffusion metrics (FA and MD) in the SN for both PD patients groups and control subjects.  
Conclusions:  SN DTI measurements are reliable and reproducible in PD patients and so can be 
used in further studies, namely longitudinal evaluation, to investigate small changes, since the 
within-subject variability of this imaging technique is low.  
 









Diffusion tensor imaging (DTI) has been widely used in the last few years to study 
neurodegenerative diseases, since it can reflect changes in the microstructural properties 
of the brain parenchyma. Recently a large number of DTI studies have focused on 
Parkinson’s disease (PD), not only investigating white matter changes (99,98), but also 
looking at grey matter alterations in specific anatomical locations related to this disease’s 
pathophysiology, especially the substantia nigra (SN)(93,153). The potential of this 
imaging technique to detect early neuropathological changes in PD makes it an attractive 
tool and a possible imaging diagnostic biomarker and research tool for improving 
knowledge on the mechanisms of the disease. The evaluation at multiple time points with 
DTI may also become very useful to enable the study of disease progression in PD.  
Compared to conventional MR sequences, diffusion-weighted images suffer from higher 
levels of image ghosting, susceptibility artifacts, eddy-currents and geometric distortions 
(154). Additionally, these sequences are very sensitive to motion effects, which are more 
frequent in movement disorders such as PD (155), with greater signal loss compared to 
T1- or T2-weigted images. This may lead to a bias when comparing images obtained in 
patients and controls, since the latter should suffer from fewer motion artifacts. All these 
factors can increase signal variability in diffusion-weighted images and so it is important 
to demonstrate the reproducibility of DTI measurements if they are going to be used as a 
tool to accurately quantify microstructural changes and progressive alterations.  
The reliability of DTI metrics has been previously studied (155-160), including in some 
movement disorders such as Huntington’s disease (161,162) that share some of the same 
imaging problems as PD. These studies have, however, presented widely variable 
estimates of the reliability of DTI measurements. These results can be related to several 
factors namely differences in imaging acquisition parameters, scanner characteristics (e.g. 
field strength), post-processing methodology (regions of interest (ROI) versus voxel-
based) and brain area specificity (158,163,164), making comparisons difficult.  
Recent studies suggested that DTI changes in the SN of early stage PD patients can have a 
very high diagnostic accuracy (93,153). These data however need further investigation, 
namely concerning the within-subject variability (i.e. scan-rescan variability), because if 
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this is large relative to the between-subject variability, then sensitivity for meaningful 
measurement alterations will be compromised.  
Our study thus investigated the reliability of DTI measurements in the SN of early-stage 
PD patients and compared it with that observed in healthy controls, through within-
scanner and test-retest studies. We quantified DTI metrics variability using the intraclass 
correlation coefficient (ICC) and investigated possible disease-related group changes that 
could influence DTI reliability. 
 
 
2. Patients and methods 
 
2.1. Patients and control subjects  
This study was a cross-sectional case-control analysis (prospective follow-up ongoing) that 
included 20 subjects: 7 “de novo” patients with PD, 7 PD patients with a 2 to 5 year 
disease duration and 6 healthy subjects. Patients were recruited from the Movement 
Disorders Unit of the University Hospital of Santa Maria-Lisbon. “De novo” PD patients 
were included at the time of clinical diagnosis if they were not on antiparkinson 
medications, provided less than 6 months had passed since the beginning of reported 
clinical symptoms. The PD patients who had been diagnosed 2 to 5 years prior to the 
study were receiving optimal pharmacotherapy with levodopa or dopamine agonists. All 
patients were diagnosed with PD by a movement disorders specialist according to the UK 
Brain Bank criteria (19) and were rated using the Unified Parkinson’s Disease Rating Scale 
(UPDRS). The healthy control subjects were recruited from local hospital staff and 
relatives. Dementia, psychiatric illness or contraindications to an MRI were the exclusion 
criteria. 
The examinations were performed with the understanding and written consent of each 
subject, with approval from the local ethics committee, and in compliance with national 
legislation and the Declaration of Helsinki guidelines. 
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2.2. MRI protocol 
 
2.2.1. Imaging protocol 
All data was acquired with a 3 T MRI system (Achieva 3.0, Philips Medical Systems, Best, 
Netherlands). For each participant three DTI scans were acquired: a first baseline scan 
(scan 1), an inside scanner repetition (scan 2), for which the patient remained inside the 
scanner, the head repositioned and a new survey was acquired for imaging planning, 
followed by a third acquisition, 15 days later (scan 3). The three DTI image acquisitions 
used the same imaging parameters. The “de novo” patients only initiated antiparkinson 
medication after the completion of the third scan.  
All images were acquired with an 8-channel phased-array head coil. DTI was performed 
using a single shot, spin-echo planar imaging (EPI) pulse sequence with the following 
acquisition parameters: repetition time(TR)/effective echo time (TE), 15755/55ms; b 
values 0, 1000 s/mm2; 32 diffusion gradient directions; flip angle, 90°; field of view (FOV), 
224mm  240mm; reconstruction matrix, 268  288; 1 average; slice thickness of 2mm 
with no gap; 80 slices and 10 min acquisition time. 
In addition, T1- and T2-weighted images of the entire brain were obtained in all subjects 
and evaluated by an experienced neuroradiologist to exclude other pathological imaging 
findings. 
 
2.2.2. Imaging analysis  
Each subject’s images from the different scans were randomly numbered and analyzed as 
independent studies to ensure that no effect of acquisition order would influence the 
results.  
Images were transferred to a Linux workstation for analysis and DTI image processing was 
performed using FSL (FMRIB, Oxford, UK, version 4.0.1)(165,166).  
Square ROIs with a predetermined size were manually drawn for each subject, with the 
researcher blinded to the subject identity and scan number. We used the same regions-
of-interest (ROI) method as described by Vaillancourt et al (93), each SN ROI with four 
voxels (voxel size 0.8360.836 mm2), were placed in the medial, central and lateral SN 
(Fig 1 A-C). All ROIs were placed bilaterally. 
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Both fractional anisotropy (FA) and mean diffusivity (MD) were extracted from all the 
ROIs for each subject. The mean FA and MD across the left and right ROIs were calculated 
and used in statistical analysis.  
 
7.3. Statistical analysis 
Differences in the clinical characteristics among these groups were assessed. Differences 
in the sex distribution among the groups were evaluated with the χ2-test. The Kruskal-
Wallis test was performed for comparison of the median age between groups as well as 
for the total UPDRS score and for part III of the UPDRS evaluation. 
The intraclass correlation coefficient (ICC) was used to assess the reliability of DTI 
measures and was calculated for PD groups and control subjects separately for each 
region. Confidence intervals (CI) at 95% were obtained for ICC values using the delta 
method. Measurement reproducibility was assessed by using the Bland-Altman method 
(167) to define the agreement between the measurements, without differentiating 
between PD and control data.  
All statistical analysis was performed with R 2.15.2. (R Foundation for Statistical 
Computing, Vienna, Austria) and a p-value of 0.05 was considered significant. 
 
8. Results 
MR imaging and DTI metrics calculation was feasible in all subjects. We analyzed data 
from 7 patients with “de novo” PD, 7 patients with 2-5 year disease duration and 6 
healthy controls (clinical characteristics shown in Table 1). No significant differences were 
observed in age and sex among the 3 groups, and there were also no significant 
differences in HY stage and UPDRS scores between the untreated “de novo” and the 2-5 
year disease duration PD patients. 
FA and MD values for the three DTI scans are summarized in Table 2. No significant 
differences were found in FA or MD values either between PD patients and healthy 
controls or between “de novo” and 2-5 year PD patients (Table 2). 
The ICCs, CIs and variance for the FA and MD values are shown in Table 3. We obtained 
high ICC (>0.6) for both metrics in the SN ROIs for both PD groups and controls and also 
when considering the values irrespective of group. For FA values, the ICC was above 0.9 
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with a very narrow confidence interval for all ROIs. The ICCs for MD values were above 
0.6 with wider confidence intervals. 
Between-subject variance was larger in the PD groups than in controls but the within-
subject variances in PD patients groups and controls were similar, varying between 0.048 
and 0.078 for FA, and between 0.020 and 0.029 for MD (Table 3).  
The analysis with Bland-Altman plots for FA and MD showed a good agreement between 
the scans with differences lying within a small range (Fig 2). Satisfactory precision 
parameters were found for the SN in all scans. 
 
9. Discussion 
We obtained high ICC (>0.96) and a very narrow confidence interval for FA diffusion 
tensor metrics in the SN, indicating a good level of reliability of this parameter for within-
scanner and test-retest evaluations. For FA values, the analysis of within-scanner and 
test-retest data reproducibility demonstrated high levels of reliability with a similar 
distribution of variability between the PD groups and controls. MD values had a higher 
variability compared to FA with lower ICCs (above 0.6) and a wider confidence interval. 
The ICC values for DTI metrics obtained here are in agreement with previously published 
studies, namely on Huntington’s disease (161,162), using test-retest (163,168) or 
between scanners (157,158,169) methodology. However, contrary to previous DTI 
reproducibility studies (161,163) the ICCs for FA metrics in our study were lower that the 
ICCs for MD in the SN in both patients and control groups. MD includes averaging across 
the tensor elements (the eigenvalues) that would be expected to increase the signal-to-
noise ratio and lead to reduced variability compared to FA. Nevertheless, our data shows 
that FA, although primarily suited for the evaluation of white matter microstructure, can 
also be used to more accurately evaluate grey matter structures even in small size 
anatomical locations such as the SN. 
Contrary to the initial study of Vaillancourt et al (93), we found no significant differences 
in the SN’s FA or MD values between PD patients and controls. However our results are in 
consonance with other posterior studies that also found no difference in the DTI metrics 
in the SN area (23). Future studies with a significantly larger number of patients are 
needed to clarify DTI changes in the SN of PD patients. 
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We obtained high within-subject agreement for both DTI metrics in the SN for all the 
groups (Table 3), in agreement with previous studies (170,171). However the levels of 
within-subject (i.e. scan-rescan) variability were higher relative to between-subject 
variability for both FA and MD which could compromise sensitivity when attempting to 
detect pathological meaningful changes.   
Between-subject variance was larger in the PD groups than in controls (Table 3), as would 
be expected, with reasonably similar within-subject variances in PD patients groups and 
controls. This implies that ICC differences observed between controls and PD are related 
to between-subject variations, and consistent with the scanning technique being equally 
reliable in both groups. 
The evaluated areas were selected because they are key anatomical locations in PD 
pathophysiology and targeted in most MR DTI studies. We used ROI manual delineation, 
despite it being time consuming and operator dependent, as it ensures a good anatomical 
correlation, taking into account the anatomical variability.  It has also been previously 
demonstrated that ROI measurements seem to be more accurate than voxelwise analysis 
(161) that requires inter-subject registration and smoothing, which may be a source of 
errors when comparing the estimated FA values.  
Acquisitions at 3.0T and higher magnetic fields are more prone to susceptibility effects, 
which vary depending on the orientation relative to the main field (156). For this reason, 
the high level of iron in the substantia nigra could have led to more variable results at 
3.0T, but these did not seem to significantly influence the diffusion signal and our DTI 
metrics.  
As there was repositioning of the subjects, the position of the head within the magnetic 
field changed between the scans and there was additionally a long time interval (two 
weeks) between scans 2 and 3. The high reliability of DTI metrics found in our study 
indicates that in longitudinal studies the consistency of head position seems to be of less 
importance when using ROI methods that compensate for the variations in the subtle 
differences in orientation and slice positioning (160).   
Our study has some limitations, namely the relatively small sample size for each group, 
even though the number is consistent with most of the published DTI studies in PD 
(93,121,172,173) and it is not expected that the degree of variability changes significantly 
with an increase in the number of subjects. 
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Additionally, we only analyzed grey matter structures, which have a very different FA 
compared with white matter, but previous studies had found similar variability in grey 
and white matter DTI parameters (161). 
Although the reliability of DTI has already been demonstrated across scanners (174), we 
used a 3.0T MR scanner and our results may not directly apply to lower magnetic fields. 
Reliability of DTI metrics can be affected by a number of factors either extrinsic (motion 
artifacts, acquisition resolution, positioning, alignment), intrinsic (MR scanner 
performance, field homogeneity, coil and gradient features) or related to post-processing 
(analysis software, data processing strategy) (156,170,171,175), so our results cannot be 
extrapolated to every DTI sequence or equipment as these inevitably influence the 
reproducibility of DTI metrics. This variability still restricts the determination of standard 
data in the study of PD with DTI metrics. 
We did not investigate inter-rater or intra-rater agreement because these issues have 
already been addressed in previous studies with satisfactory to very good results for most 
anatomic locations (156,170,175). However, these may still be problematic when 
interpreting FA and MD maps with an ROI analysis where the variability is mainly related 
to the anatomical training of the observer in the correct selection of the location to 
analyze (175). It would be beneficial, therefore, to have more than two observers 
analyzing every ROI and to evaluate additional locations, although it should be safe to 
assume that our findings can be extrapolated to other grey matter brain areas.  
In diseases such as PD, where the expected differences between patients and controls 
may be quite subtle, it is important to characterize the regional variation of the studied 
metrics to ensure a correct interpretation of group comparisons (163). Our data indicate 
that in the studied grey-matter ROIs, relevant for PD pathology investigation, DTI FA 
metrics can be reliably used in future studies since variability of repeated measurements 
have no significant influence on the results. We found no evidence of group bias that 
could have influenced reliability. 
In conclusion, the low within scanner and scan-rescan variability, as well as the 
homogeneity among the anatomical sites in terms of DTI metrics reliability gives support 
to the further use of these imaging parameters for the detection of brain structural 
changes in PD.  





We obtained high ICC for MD and especially FA diffusion tensor metrics, indicating a good 
level of reliability of these parameters. These findings give support to the use of these 
measurements in further studies, namely longitudinal within-subject evaluation, and 
cross-sectional comparisons.  
 
  




Tables and legends 
 










7 (5/2) 7 (2/5) 6 (2/4) 0.2852 
Age, years 
(mean±SD) 
67(52-82) 68(62-78) 61(49-72) 0.3451 
H&Y (mean±SD) 2(2-2) 2(2-2) - - 
Total UPDRS 
(mean±SD) 




24(15-50) 26.5(17- - 0.8301 























0.53 (0.16) 0.50 (0.21) 0.53 (0.13) 1.00 1.00 1.00 
RM In scanner 
0.53 (0.14) 0.52 (0.17) 0.53 (0.12) 1.00 1.00 1.00 
RM 15 days 


















0.78 (0.14) 0.81 (0.09) 0.78 (0.08) 0.45 1.00 1.00 
RM In scanner 
0.83 (0.11) 0.76 (0.24) 0.76 (0.13) 1.00 0.16 0.10 
RM 15 days 
0.81 (0.13) 0.77 (0.14) 0.76 (0.09) 1.00 1.00 0.61 
*Comparisons using Kruskal-Wallis test 
PD: Parkinson’s Disease; y: year 
 
 





Table 3: Intraclass correlation coefficient (ICC) for mean FA and MD values  
 







































































Fig 1. ROI manual tracing 
Manual tracing of SN ROIs in the b0 image (a) correspondent FA (b) and color coded map (c).  
(a) (b) (c) 





Fig. 2. Bland-Altman plot for SN FA values 
Agreement systematic bias and proportional bias analysis of fractional anisotropy (FA) (a-c) and 

























3. MR IMAGING FOR THE DIFFERENTIAL DIAGNOSIS  
OF PARKINSON’S DISEASE 
  








The differential diagnosis of PD with Essential tremor (ET) and atypical parkinsonian 
syndromes (APS), including multiple-system atrophy (MSA), supra-nuclear palsy (PSP) and 
cortico-basal degeneration (CBD) can be challenging.  So far, much of the interest on 
imaging approaches in this context has focused on nuclear medicine techniques with 
specific metabolites, in particular 123I-ioflupano (DaTSCAN), since they allowed an 
evaluation of dopaminergic function and the detection of nigro-striatal disfunction with 
high sensitivity and specificity for PD diagnosis (176). However the high cost, low 
availability and exposure to ionizing radiation (177) limit the clinical application of these 
methods that also have an overlap with normal subjects in PD early stages (178), in spite 
of the high accuracy values, and do not allow the distinction between PD and APS such as 
MSA or PSP (176). 
MR imaging studies have an increasing relevance in the differential diagnosis of PD with 
APS and ET, through the analysis of morphological, functional and microstructural 
information in specific anatomic areas. 
Essential tremor (ET) is one of the most prevalent neurological disorders and the most 
frequent cause of tremor (179). Clinically, ET shares important features with 
neurodegenerative disorders but the pathophysiology of the disease remains unknown 
(180). The differential diagnosis of ET from PD assumes a great importance not only in 
establishing the adequate therapy but also in defining prognosis. However, the clinical 
differentiation between these conditions can be challenging in the early stages of the 
disease (181,182) and so additional studies might significantly help to increase diagnostic 
accuracy.  
A significant number of imaging studies have focused on ET, using morphological and 
functional information (183-185) trying to investigate specific disease changes that might 
help to understand the pathophysiological mechanisms of the disease and to differentiate 
ET from other tremor conditions. 
A T2* relaxometry study in 3.0Tesla MR has shown an increased iron deposition in the 
globus pallidum, SN and right dentate nucleus of ET patients, raising new hypothesis as to 
the pathophysiology of this disease and the motor pathways involved in tremor genesis 
(186). Also DTI studies found specific disease microstructural pattern changes in ET that 
are different from other tremor conditions (187, 188).  
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These studies suggested that the SN might have pathological changes in ET patients, 
sharing some similarity with PD. Neuromelanin sensitive MR imaging in PD had found 
disease specific changes but the SN neuromelanin had not yet been studied in ET. So we 
evaluated the SN neuromelanin MR signal in ET patients, analyzing the possible detection 
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Background: Essential tremor (ET) is a very common movement disorder that has no diagnostic 
markers. The differentiation with Parkinson’s disease (PD) can be clinically challenging in some 
cases, and there is a high rate of misdiagnosis. MRI studies have been able to identify 
neuromelanin changes in the substantia nigra of PD patients, but they have thus far not been 
investigated in ET. In this study, we aimed to characterize neuromelanin-MR signal changes in ET 
and evaluate its diagnostic accuracy in the differential diagnosis with PD. 
Methods: The inclusion criteria were patients with ET and untreated “de novo” PD patients; in 
addition, age matched controls were enrolled. These were studied with a high-resolution T1-
weighted MR imaging sequence at 3.0 Tesla to visualize neuromelanin. The primary outcomes 
were the area and width of the SN region with high signal.  
Results: A total of 15 ET patients and 12 “de novo” PD patients were evaluated. The area and 
width of the T1 high-signal in the SN region were markedly decreased in the PD group compared 
with the ET and age-matched controls, and there was a greater decrease in the ventrolateral 
segment. The neuromelanin measures in the ET group although slightly lower were not 
significantly different from the healthy control group. We obtained a sensitivity of 66.7% and a 
specificity of 93.3% in discriminating ET from early stage PD.  
Conclusions: Neuromelanin-sensitive MRI techniques can discriminate ET from early stage 
tremor-dominant PD and can be a useful clinical tool in the evaluation of tremor disorders.  









Essential tremor (ET) is a very common neurological disorder (189-192), that has an 
estimated prevalence of approximately 5% in the population over 65 years of age 
(179,193). ET is clinically characterized by a symmetric 4- to 8Hz action tremor that most 
frequently affects the hands and arms, but it can also involve the head (194). Typical ET 
cases can be easily diagnosed and distinguished from Parkinson’s disease (PD), which is 
characterized by an asymmetrical 3- to 5-Hz resting tremor (181). However, the clinical 
differentiation between these conditions can be challenging, and there is a considerable 
overlap in the clinical features, particularly in the early stages of the disease (181,182). 
This differentiation is very important in defining prognosis and treatment decisions and in 
identifying patients for research, but a high rate of ET misdiagnosis has been described in 
several studies (195-198), emphasizing the need for additional diagnostic evaluation. 
The etiology of ET is unknown, and its pathophysiology is still poorly understood.  Several 
MRI studies have investigated the morphological and functional brain alterations in ET 
patients (187,199,200), and some pathological studies have recently shown evidence of 
structural brain changes in this disease that might be associated with neurodegeneration 
(201). 
Recent imaging studies have reported changes in the SN of ET patients with an increased 
echogenicity in sonography studies (202,203) and MR T2*-relaxometry signal reduction 
(186), suggesting the involvement of the SN and nigrostriatal degeneration as in 
Parkinson’s disease (PD).  
PD is characterized by depigmentation of the substantia nigra pars compacta (SNpc) and 
of the locus coeruleus (LC), which is related to the loss of neuromelanin (35). Over the few 
last years, new MRI sequences have been able to detect a significant reduction in the SN 
neuromelanin signal in PD (61-63,132), and these changes have a high diagnostic 
sensitivity and specificity for PD diagnosis, even in the very early clinical stages.  
Despite the identified SN changes in ET, the SN neuromelanin changes in ET have not 
previously been studied. In this study, we analyzed the neuromelanin MR signal pattern in 
ET and the accuracy of this imaging technique in the differential diagnosis with early stage 
PD.  To the best of our knowledge, this is the first study of MR neuromelanin imaging in 
ET.  
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2. Patients and methods 
2.1. Patients and control subjects  
The study had a cross-sectional case-control design that included 37 subjects, 15 patients 
had ET, 12 patients had “de novo” PD, and 10 were control subjects. Patients were 
recruited from the Movement Disorders Unit of the University Hospital of Santa Maria-
Lisbon.  The PD patients were included at the time of clinical diagnosis if they were not on 
antiparkinson medications. All patients were diagnosed by a movement disorders 
specialist and fulfilled the ET criteria of the Movement Disorder Society on Tremor (204) 
or the PD UK Brain Bank criteria (19). The healthy control subjects were recruited from 
local hospital staff and relatives. Dementia, psychiatric illness or contraindications to an 
MRI were the exclusion criteria. 
All examinations were performed with the understanding of and written consent from 
each subject, with approval from the local ethics committee, and in compliance with 
national legislation and the Declaration of Helsinki guidelines. 
 
2.2. MRI protocol 
2.2.1. Imaging protocol 
All data were acquired using a 3.0 -Tesla Phillips scanner (Phillips Achieva). The 
following neuromelanin-sensitive pulse sequence was used as previously described by 
Sasaki and colleagues (61): T1-weighted FSE: repetition time/effective echo time, 633/10 
ms; echo train length, 3; number of slices, 20; slice thickness, 2.5 mm; intersection gaps, 0 
mm; matrix size, 548 x 474; field of view, 220 x 190 mm2 (pixel size: .40 x .40 mm2); and 
acquisition time, 8 min. The sections were carefully set in the oblique axial plane 
perpendicular to the fourth ventricle floor, with coverage from the posterior commissure 
to the inferior border of the pons.  
T1- and T2-weighted images of the entire brain were additionally obtained in all subjects 
and evaluated by an experienced neuroradiologist to exclude other pathological imaging 
findings, namely, changes in the parkinsonian index and other atypical parkinsonian 
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2.2.2. Imaging analysis  
Images were transferred to a Linux workstation for analysis, and an edge preserving filter 
(122) was applied using Matlab (R2012a, The Math Works, Natick, MA, USA) to reduce 
the image noise. T1 high signal in the SN region was visible in 3 slices, and the middle slice 
corresponding to the greatest SN volume was selected (Fig 1 A-C). A rectangular region 
was then selected in this slice, and two symmetrical seed points were manually defined 
on the most medial part of the high-intensity area in the SN. A region growing algorithm 
(123) was used for segmentation starting from each seed point, and the area of interest 
(AOI) was automatically drawn. Pixels with a signal intensity within the interval Iseed  
0.035(Imax-Imin) were labeled as belonging to the AOI, where Iseed is the intensity at the 
seed point, and Imax and Imin are the maximum and minimum signal intensities, 
respectively, within the rectangular mesencephalon ROI. The threshold used to delimit 
the AOI was chosen after a preliminary optimization study using healthy controls and PD 
patients (139) in which the threshold was varied using a batch process; the final value of 
3.5% was selected since it provided a better visual fit to the anatomical area. The optimal 
threshold value depends on the contrast and signal-to-noise ratio of the input images, 
and so it should be adjusted for each specific set of acquisition conditions – imaging 
sequence, and coils used for signal reception. The area of interest (AOI) was automatically 
calculated (Fig 1D-F). As there were no significant differences regarding side for the SN 
area measurements, the median value was obtained from an average between the left 
and right neuromelanin area obtained for each subject. 
Additional manual measures were performed in the same slice used for the automatic 
measurements. The high signal region was selected in this slice, and a line was defined 
following the maximal longitudinal length of the SN area. This line was divided into three 
equal segments defining the lateral, central and medial SN parts. One of the authors 
(R.S.), who was blinded to the subject information, performed manual measurements of 
the maximal width of the T1 high signal area perpendicular to the length line for the three 
SN parts, as shown in Fig 1G. Measurements were performed on both sides and as there 
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9.3. Statistical analysis 
The SN high signal area and width obtained for each group were compared using non-
parametric analysis. Kruskal-Wallis tests, with pairwise comparisons in which the resulting 
p-values were corrected according to Bonferroni method, and Mann-Whitney U tests 
were used as appropriate. A p-value below 0.05 was considered significant. Receiver 
operation characteristics (ROC) curve analysis was conducted to assess the discrimination 
capacity of the measures, SN area and width, for ET and PD as well as PD patients and 
controls; additionally, the specificity and sensitivity values were obtained. Optimal cutoff 
points were assessed through a method that simultaneously maximized the sensitivity 
and specificity. The area under the curve (AUC) was also assessed. All statistical analysis 
was performed with R 2.15.2. 
 
10. Results 
The obtained MR imaging quality allowed for the clear identification of the high-signal 
area in the SN region in all subjects. The automated analysis and manual width 
measurements were possible on all acquired images. We analyzed 15 patients with ET, 12 
patients with “de novo” PD, and 10 controls. The clinical characteristics of these subjects 
are shown in Table 1. The ET patients were older than the “de novo” PD patients and 
controls; no significant differences were observed in sex among the 3 groups (p-value = 
0.925). ET patients had a median disease duration of 10 years (3-21 years). PD patients 
had a mild disease severity with H & Y of 2 and a mean UPDRS motor score of 29.08. 
Tremor of the hands was the presenting symptom in 11 of the 12 PD patients with only 
one patient presenting with an akinetic-rigid form. Symptoms at onset were 
predominantly unilateral with half of the patients presenting criteria for asymmetric 
disease on UPDRS part III (141). 
Using an automated analysis of the SN high signal, we obtained a median area of 19.76 
mm2 for the “de novo” PD patient group, 25.77 mm2 for the ET group, and 27.78 mm2 for 
the controls. We found no significant differences between left and right SN areas (p-value 
= 0.630). 
In the lateral part of the SN, the manually measured median width of the T1 high signal 
was 1.5 mm, 2.0 mm and 2.4 mm in the PD, ET and healthy control groups, respectively. 
In the central part, the median width was 2.5 mm, 3.2 mm and 3.3 mm in the PD, ET and 
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healthy control groups, respectively. In the medial segment, the median widths were 3.4 
mm, 3.8 mm and 3.8 mm in the PD, ET and healthy control groups, respectively. If we 
considered all of the SN segments, the average width of the manually measured T1 high 
signal was 2.5 mm in the “de novo” PD patients, 3.2 mm in ET group and 3.2 mm in the 
healthy control group.  
The measured area of the SN T1-high signal was only slightly reduced in the ET patients 
compared to controls with a p-value >0.05, but it was markedly decreased in the PD 
group compared with the ET and healthy control groups; the p-value was <0.001 for both 
comparisons (Fig 2).  
In the ET group we identified 2 outliers whose SN area was above the superior level of the 
control group (Fig 2). To see how the outlying observations could influence the results we 
removed them and performed a sensitivity analysis. Excluding the outliers the SN 
neuromelanin median area in ET patients was 25.54 mm2 and the group comparisons 
yielded similar results with a significant reduction in the neuromelanin SN high-signal area 
in PD patients compared with ET and controls (p-value <0.001) and no significant 
differences between the ET patients compared with controls (p-value = 0.909). The SN 
neuromelanin manual width measurements were reduced in the PD group compared 
with ET and controls with p-values of 0.002 and <0.001, respectively. The greatest 
reduction was evident at the lateral and central SN segments with p-values of <0.001 and 
=0.005, respectively (Fig 3). Two outliers were identified in the lateral SN segment (1 
control and 1 ET patient) (Fig 3), with measured width close to zero. We reviewed these 
images and the lateral midbrain region had reduced image quality which might have 
influenced the visual identification of the T1 high signal area image and the manual 
measurement. We did not find any significant differences between the ET and control 
groups for the neuromelanin SN measurements (p-value = 0.261), using either method, 
although the median measurements of the ET group tended to be slightly lower than the 
controls (Fig 2 and 3). 
The sensitivity and specificity of the SN high signal area for discriminating the ET patients 
from the PD patients were 66.7% and 93.3%, respectively, when the cut-off value for the 
area was set at 24.08 mm2.  
The sensitivity and specificity for discriminating the “de novo” PD group from the control 
group were 70.8% and 80%, respectively, with an area cut-off value of 24.08 mm2 (Fig 4). 




In the present MRI study, we were able to detect significant differences in the 
neuromelanin SN pattern of ET compared with PD. In ET, the neuromelanin in the SN was 
not significantly reduced compared with the healthy control group, but the PD patients, 
even at the time of clinical diagnosis, exhibited a significant reduction in the SN T1-high 
signal, which was more pronounced laterally in accordance with the known pathological 
changes (141). Using different SN neuromelanin signal measurement methods, i.e., 
manual and semi-automated, we obtained similar findings for the T1-high signal area and 
width, enabling the differentiation of ET patients from the “de novo” PD group with very 
high sensitivity and specificity. 
It is known from pathological studies that the neuronal loss in PD occurs asymmetrically 
and early in the course of PD or even in preclinical stages (9), and that it is more 
pronounced in the ventrolateral region of the SNpc with relative preservation of the 
dorsal region (14). We used manual width measurements additionally to the automated 
global area to study the pattern changes in the different segments of the SN T1 high 
signal region. In agreement with previous neuromelanin studies (61-63,125), our 
neuromelanin data reproduce the SN pathological findings in PD, suggesting SN 
neuromelanin neuronal depletion in patients with early PD that is absent in ET or healthy 
individuals. We were not able to find a significant asymmetry in the SN area nor a 
correlation with the clinically most affected side in our PD patients. This may be due to 
the small number of subjects in our samples that limits our power.  
Considering the reported sonography changes of the SN in ET (202,203), our data show 
that, contrary to the findings in PD, the increased echogenicity of the SN in ET is not 
related to a reduced SN neuromelanin content. These sonography changes might only be 
related to the increased tissue iron content in ET, which has been recently documented in 
an MR quantitative study (186). Our results corroborate the hypothesis that iron 
deposition and neuromelanin loss might be separate processes that are related to 
different pathological processes and variable clinical manifestations, such as specific 
tremor characteristics. The correlation of neuromelanin and the iron content of the SN 
requires further investigation and the determination of the different disease pathological 
patterns that affect the SN in ET and PD and result in different clinical characteristics. 
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Although the clinical diagnosis of ET in typical cases requires no further diagnostic 
investigation, in the subset of patients with atypical signs and symptoms, particularly in 
the early disease stages, there can be a significant benefit from further diagnostic 
evaluation because the distinction with PD has important therapeutic and prognostic 
consequences. In this study, the obtained moderate sensitivity and high specificity for 
MRI neuromelanin studies are only slightly lower than those obtained in 123I- FP-CIT 
SPECT studies in discriminating ET from PD (134,137,198). This MRI technique is safe and 
widely available; as a result, it might have the potential to become an alternative to the 
more expensive nuclear medicine techniques that have additional risks (134) in the 
diagnostic evaluation of tremor disorders.  
However, our study has several limitations, including the small number of patients in each 
group and the absence of pathological confirmation. The small sample size of our study 
groups limits the precision of the obtained estimates of sensitivity and specificity, and so 
further studies are needed to strengthen the performance characteristics of this imaging 
method in the distinction between PD and ET patients.  
Another aspect is related to the disadvantages of the imaging technique, including the 
long acquisition time, the relatively low spatial resolution and the existence of in-plane 
signal inhomogeneity. Slice positioning and partial voluming may be confounding factors 
in surface-based measurements, which could potentially be improved by using a three-
dimensional acquisition (127). 
Additionally, the region-growing post-processing technique used in this study for the 
semi-automated measurement of areas requires the determination of seed points and 
normalization of signal intensity that could not be completely automated. Although the 
same criteria were followed for the placement of the seed points on each image, in the 
future the impact of varying their position on the estimated neuromelanin SN area should 
be investigated so as to determine the reproducibility of this method. 
The total imaging analysis is relatively time consuming and requires the implementation 
of post-processing software that is not widely available. However, the manual analysis 
yields very similar results, and, although it is operator-dependent, it is very fast and 
widely available without the need for post-processing software. The within-subject and 
inter-rater reproducibility of MR neuromelanin measurements has not been fully 
established, and so the reproducibility of these parameters needs to be addressed in 
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further studies, especially concerning the manual analysis, in order to allow a wider 
implementation of this imaging technique. 
Motion artifacts were not a problem in either the ET or PD groups, but these were early 
stage patients. Advanced-stage patients with exuberant tremor might have artifact 
problems that will require further adjustments. 
Two outliers (1 control and 1 ET patient) had neuromelanin lateral SN widths close to zero 
which could be related to the poor image quality in the lateral midbrain region. A possible 
source of subject-dependent contrast variation is the effective B1 field which is 
determined by the electrical properties of the tissue (its conductivity and permittivity). In 
the future, the acquisition protocol should be further optimized, so as to improve image 
contrast and consistently enable good visualization of the SN. 
The number of patients in our study did not allow statistical correlation with clinical 
severity or age group correction of the SN neuromelanin measurements. However a 
previous neuromelanin MR study with 80 PD patients found no correlation between age 
and neuromelanin SN volumes in PD patients or control subjects (63) and so it is not likely 
that age would be an influencing factor in our results, although it is something we can not 
completely exclude. In the same study the authors found an inverse correlation between 
neuromelanin-sensitive SN volume and the Hoehn and Yahr stage and disease duration in 
PD patients. 
Our small sample does not allow PD patient’s stratification in clinical sub-types for further 
analysis but almost all our PD patients had tremor as the presenting symptom. It is known 
that akinetic-rigid and tremor-dominant subtypes of PD have different neuropathological 
patterns (205), with greater SN neuronal loss in akinetic-rigid patients (with ventrolateral 
predominance) compared with tremor-dominant patients (with medial predominance) 
(206). We found a significantly different SN neuromelanin pattern in ET versus PD 
patients, in agreement with the known absence of pathomorphological SN changes in ET, 
but further studies are needed to specifically investigate the difference in neuromelanin 
SN MRI changes in PD clinical subtypes. The obtained sensitivity for PD patient’s 
discrimination was lower than the specificity which might be intrinsically related to SN 
neuromelanin changes in PD. The current understanding of the relationship between the 
extent of dopamine cell loss and the clinical manifestations of PD remains unclear and 
previous dopaminergic brain imaging studies have reported that some PD patients with 
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mild symptoms have no evidence of dopaminergic dysfunction (178). Also the SN 
neuromelanin volume may not directly reflect the dopaminergic function since 




MR neuromelanin-sensitive images were able to accurately distinguish ET from tremor-
dominant PD patients even at the time of PD clinical diagnosis. We detected significant 
neuromelanin changes, in the SN of PD patients that are not present in ET, highlighting 
the different pathological processes in the SN of these two tremor conditions. MRI 
neuromelanin-sensitive techniques might become a useful diagnostic tool for the 
differentiation of ET from PD in very early clinical stages. 
 
 
Table and Figure legends 
 
Table 1: Demographics for Essential tremor, Parkinson’s disease and control subjects 
  ET PD  Controls p-value 
No. 
(female/male) 
15 (8/7) 12 (7/5) 10 (4/6) 0.925 
Age, years 
(mean±SD) 




- 29.1(±14.2) - - 








Fig. 1. SN neuromelanin-MRI of a control (A), an ET (B) and PD patients (C); segmented 
areas in the same groups: control (D), ET (E) and PD patients (F); the crosses in (D) 
represent the placement of the seed points in that specific subject; width measurement 




Fig. 2. Area of the SN high-intensity region on neuromelanin-sensitive MR images in 
patients with ET, “de novo” PD and controls; p-values, Mann-Whitney U-test. 
 




Fig. 3. Width of the SN high-intensity region on neuromelanin-sensitive MR images in 
patients with ET, “de novo” PD and healthy controls p-values, Mann-Whitney U-test. 
 
Fig. 4. ROC curve of the area for differentiating between ET and “de novo” PD patients. 
 



























PD diagnosis in early and even pre-motor stages is a particularly relevant topic, not only in 
view of the need of a precocious implementation of an adequate therapeutic plan but 
also in light of the possible development of disease modifying treatments. 
For many years, neuroimaging studies in PD focused on the investigation of established 
disease, looking at specific disease alterations and trying to ascertain clinical correlations. 
However, even in very advanced disease stages, MR studies with conventional sequences 
were very discouraging, failing to depict disease changes, namely in the SN, that could 
influence the diagnosis or establish a correlation with disease progression (24).  
The characteristic PD pathological changes, identified post-mortem in early and pre-
clinical disease stages (9), were undetectable by neuroimaging studies in vivo. Particularly 
the characteristic depigmentation of the SN related to the loss of the pigment 
neuromelanin was undetectable by neuroimaging techniques. However, the development 
of advanced MR techniques in high field magnets opened new possibilities to study brain 
neurodegeneration. Finding valid imaging biomarkers has become an important field of 
research that might have a significant impact in clinical practice and even influence 
etiological and pathophysiological disease comprehension.  
Our work had as a main objective the application of new MR imaging techniques to study 
the SN in PD, early in the disease course, mainly focusing on untreated patients at the 
time of clinical diagnosis. Early-stage PD, especially nonmedicated patients, were 
considered the best group to evaluate the impact of imaging methods in early disease 
identification and differential diagnosis. The imaging analysis sought a complementary 
multimodal evaluation to visualize the SN changes, with the neuromelanin sensitive 
sequences assuming a particular emphasis. Iron quantification and its interaction with 
neuromelanin and DTI microstructural changes were additional imaging parameters that 
allowed a complementary analysis of PD changes.  
The performed MR imaging protocol was initially delineated and optimized to the PD 
population, focusing on some particular aspects that could interfere with image 
acquisition, especially movement artifacts from involuntary movements. The protocol 
was feasible and we find it easy to implement widely in a clinical setting with a high-field 
3.0T machine. The developed imaging analysis tools, with easily usable interfaces, have 
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allowed an efficacious evaluation of the different studied parameters and may have a 
significant impact on the implementation of imaging analysis on the clinical practice. 
The first line of our research focused on the diagnosis of early-stage PD with MR 
imaging. Neuromelanin sensitive MR imaging of early stage PD was initially evaluated 
with a semi-automated analysis to determine the area and length of the SN high signal 
area in early disease stages. The developed graphic post-processing user interface 
allowed a fast and easy visualization of the neuromelanin SN region and the extraction of 
measurements using a “region-growing” algorithm. Although not entirely automated, this 
analysis is very operator independent and widely usable. The imaging filters were 
additionally optimized for image analysis which allowed an improved reliability of the 
measurements.  
Our study was innovative not only for analyzing the neuromelanin of PD patients but also 
for applying these imaging techniques to study “de novo” unmedicated patients with a 
post-processing imaging analysis not based on anatomical segmentation. This study 
allowed the detection of significant changes in the SN neuromelanin of PD patients 
compared with controls with a high sensitivity and specificity for the disease diagnosis. 
We were additionally able to reproduce in vivo the characteristic pathological disease 
pattern changes in the SN with a greater alteration in the ventrolateral SN and 
preservation of the dorsal segment (14). 
In our analysis we did not find a significant difference in the neuromelanin measurements 
between “de novo” and 2 – 5 year disease patients. These data were in agreement with 
previous studies, not only MR neuromelanin analysis (125) but also transcranial 
sonography (126) in which the SN signal did not seem to change through the course of 
the disease.  
Considering the clinical implementation of our results, easy and widely available imaging 
analysis without the need of a post-processing software was needed for current usage. So 
we compared quantitative methods with a simple visual analysis of the neuromelanin 
sensitive MR images in early stage PD patients to evaluate the feasibility and accuracy of 
these analyzing methods. The image visual inspection by experienced neuroradiologists 
had as good results as a quantitative width analysis of the SN neuromelanin area, which 
can favor a future implementation of this technique in the clinical practice. 
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As a whole, the neuromelanin sensitive MR imaging in early stage PD diagnosis was 
feasible using different imaging post-processing options, either quantitative or with 
simple visual inspection, using semi-automated or manually demarcated areas, and with 
all the approaches we were able to detect a significant reduction of the SN neuromelanin 
in PD patients compared to controls with a disease characteristic pattern that reproduces 
the known pathological changes (14). The different methodology used for imaging 
analysis in these studies further validates the findings. 
The need for additional research of the neuromelanin correlation with disease 
progression and with the applied therapy aroused from our data analysis and motivated 
additional studies that are already in course.  
The possible use of these imaging analysis in pre-clinical stages, namely in subjects with a 
familial history, asymptomatic genetic mutation carriers or in the investigation of disease 
risk factors such as exposure to pesticides, the relationship with the protective effect of 
tobacco smoke and the correlation of brain neuromelanin in melanoma patients are 
projects that we have already delineated and that we expect might contribute in the 
future to an additional understanding of the disease pathological processes.  
 
All previously published MR neuromelanin studies referred as a significant limitation not 
being able to ascertain how the SN iron content in the SN influenced the neuromelanin-
sensitive MR signal changes in PD (62,63). To investigate the correlation and the possible 
contribution of the iron content in the different segments of the SN to the neuromelanin 
signal changes in PD, we combined a specific neuromelanin-sensitive MR sequence with a 
iron quantification analysis using T2*-relaxometry at 3.0T to study early-stage PD 
patients. 
We found very weak correlations of T2* values with neuromelanin width, positive for 
global and medial SN and negative for lateral and central segments. The SN neuromelanin 
width was markedly reduced in the “de novo” and 2-5 year PD groups compared with 
controls in all SN segments but no significant difference in T2* values was found between 
the groups.  
Our data showed that iron content in the SN does not significantly influence 
neuromelanin signal changes in PD patients and is probably not a limiting factor in the 
evaluation of neuromelanin pattern changes. The identifiable reduction of neuromelanin 
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in the SN of early stage PD does not seem to be influenced by the local iron load, 
answering previous questions as to this would be a limitations in the interpretation of 
these imaging findings. 
The evaluation of the iron brain content with MRI is a very important line of future 
research, with quantitative and qualitative analysis that needs to be reproducible across 
sites. The combined analysis of iron with other parameters namely diffusion tensor 
metrics may add new data to the comprehension of the multifaceted process of 
neurodegeneration in PD. The investigation of other brain areas other that the SN in 
terms of iron content may depict the global brain involvement by the disease, and we are 
already conducting studies to evaluate changes in the basal ganglia and motor cortex of 
PD patients. Additionally, the iron distribution patterns in other parkinsonian syndromes 
and ET, namely in the SN, basal ganglia and motor cortex may give an insight as to the 
differences in pathophysiology of the different syndromes. We have already developed a 
project to analyze quantitatively the differences between PD and ET in several brain 
areas. 
 
MR DTI studies have recently focused on Parkinson’s disease, looking at grey matter 
microstructural alterations in specific anatomical locations related to disease 
pathophysiology, especially the substantia nigra (93,153); the potential of this imaging 
technique to detect early neuropathological changes in PD made it an attractive tool 
emerging as a possible imaging diagnostic biomarker and a research tool for improving 
knowledge on the mechanisms of the disease. The evaluation at multiple time points with 
DTI may also become very useful in PD enabling the study of disease progression. 
The reliability of DTI metrics has been previously studied (157,158), including in some 
movement disorders such as Huntington’s disease (15,162) that share some imaging 
problems with PD, but these studies shown a widely variable estimate of the reliability of 
DTI measurements and so it was important to demonstrate the reproducibility of DTI 
measurements in PD patients if these were going to be used as a tool to accurately 
quantify microstructural changes and its progressive alterations.  
Our study investigated the reliability of DTI measurements in the SN of early-stage PD 
patients and compared them with healthy controls, through within-scanner and test-
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retest studies. We obtained high ICCs indicating a good level of reliability for all diffusion 
metrics (FA and MD) in the SN of both PD patients and control subjects.  
The fact that SN DTI measurements are reliable and reproducible in PD patients validates 
it’s usage in further studies, namely longitudinal evaluation, investigating small changes in 
this anatomical location.  
 
The second line of our research focused on the differential diagnosis of PD with ET with 
MR imaging. The importance of a establishing a correct diagnosis at early disease stages 
is well recognized; compared to MR the currently used nuclear medicine techniques 
(134,137,198) are more expensive and have additional risks (134) which motivated our 
research in the MR diagnostic evaluation of tremor disorders.  
We studied the SN neuromelanin MR imaging of ET patients, analyzing the high signal 
area and comparing it with PD patients and controls. In ET we found no identifiable 
change of the neuromelanin measurements compared to controls. Our data showed that 
contrary to PD patients, in ET the described sonography changes (202,203) are not related 
to a neuromelanin reduction but are probably associated with increased iron content, in 
agreement with a recent MR study that showed increased iron load in ET (186). So, our 
data seems to point to the hypothesis that iron deposition and neuromelanin loss might 
be separate processes related to distinct neuropathological processes and different 
clinical manifestations. This was the first study analyzing in vivo the neuromelanin in ET 
and our results have shown a high sensitivity and specificity of this imaging technique for 
the differential diagnosis with PD. 
 
There are some overall limitations to our investigation that are common to the study 
design including the small sample size of our study groups and the absence of 
pathological confirmation of PD. However, all the subjects were evaluated by a 
Neurologist, specialist in movement disorders, and the established criteria for PD and ET 
diagnosis were fulfilled. The number of patients in our study groups also did not allow 
statistical correlation with clinical characteristics.  
The acquisition protocol and the performed imaging analysis have additional limitations. 
The selected multi-modal imaging protocol has disadvantages intrinsic to the specific 
sequences and also related to a long acquisition time of the whole protocol; the total 
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imaging analysis is also relatively time consuming, the post-processing software used in 
these studies is not fully automated or widely available, which might preclude the full 
implementation of this imaging protocol on a daily basis. Our findings are specific to a 
high-field 3.0T MR scanner and are not directly applicable to 1.5T scanners, further 
limiting its application. Motion artifacts were not a problem in the studied groups, but 
these were early stage patients; some adjustments may have to be made when dealing 
with advanced-stage patients with exuberant tremor. 
Further studies are needed to strengthen the performance characteristics of this imaging 
method for PD diagnosis and in the distinction between PD and ET patients, extending 
these findings even to lower field magnets, analyzing the correlation of the different 
parameters with clinical characteristics and studying disease progression.  
 
Looking at the global work developed in this dissertation two developed domains were 
especially relevant to allow the concretization of the achieved results: the establishment 
of a collaborative research network and the implementation of a study group devoted to 
this area of investigation. Research networks are critically important tools for research 
concretization in the field of neurodegenerative diseases, namely PD, that share multi-
disciplinary interactions; these are vital to the comprehension of the disease and to the 
development of the most adequate care of individual patients. The implementation of an 
effective study group that aggregates professionals from different areas, namely 
neurologists, neuroradiologists and physicists was the basis support platform to support 
the long term research needed to achieve meaningful results. 
At the beginning of this work, two major research and development paths were defined: 
diagnosis of PD at early disease stages and differential diagnosis with ET with 
neuroimaging MR techniques.  During the development and concretization of the 
different studies a multi-modal MR protocol was defined and optimized with a particular 
emphasis in the in vivo visualization of neuromelanin and this was found to have a 
significant impact in the diagnosis of early-stage PD and its differential diagnosis with ET. 
These findings opened a path for ongoing and future research that can change the 
neuroimaging investigation of PD at early disease stages and support new perspectives 
focused on the design and improvement of imaging tools to support decision making at a 
crucial stage of disease management. 
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The recognizable complexity of neurodegenerative processes in PD and its systemic 
involvement highlights the importance of obtaining data from a combination of 
neuroimaging evaluation tools, looking at different processes. A multi-modal MR 
evaluation may help to explore new questions related to disease pathophysiology and the 
interaction of different concurrent processes, namely concerning neuromelanin and iron, 
with a possible impact in future therapies. 
Future lines of research soon emerged from are work, some of which are already being 
pursued, with particular emphasis on the neuromelanin sensitive-MR imaging, focusing 
on technical upgrading and validation issues, imaging analysis optimization, and a 
posterior extension to the evaluation of other PD groups particularly pre-manifest genetic 
PD mutation carriers and melanoma patients; the study of therapeutical effects and 
disease progression with clinical correlation using the same imaging protocol is already 
ongoing. We highlight that the use of standardized MR protocols may allow between sites 
comparisons and the definition of guidelines to patients management and this may allow 
future evaluation of therapeutical effects and aid the definition of clinical trials. 
The developed imaging protocol is feasible and widely implementable without the need 
of sophisticated post processing tools or time consuming approaches. 
The change of perspective concerning neuroimaging in PD, evolving from a simple 
exclusion of secondary causes to a true investigation of disease mechanisms and 
emergence of biomarkers with impact in disease diagnosis needs to be pursued and 
improved in order to make an impact in clinical practice and patient’s management.  
  



























The present dissertation is the culminate result of an investigation project developed 
using MR imaging to study the SN in PD at early disease stages. The conducted work has 
allowed the implementation of a new imaging approach to study PD and the construction 
of a multi-disciplinary team focused on this area of research. It was possible to develop 
efficacious tools, of easy clinical application, with high sensitivity and specificity for PD 
diagnosis, even at the time of clinical diagnosis, which might significantly change the 
indications of MR imaging methods for the study of PD.  
Our studies with neuromelanin sensitive MR imaging have shown a high sensitivity and 
specificity of these imaging methods for PD diagnosis and an apparent stability of this 
pigment with disease progression. This new imaging technique at 3.0T has also allowed 
the differential diagnosis with ET patients that were found to have no significant SN 
neuromelanin changes, with accuracy similar to the nuclear medicine methods. These 
findings may significantly impact the evaluation of tremor disorders.  
The comprehension of the interaction of neuromelanin and iron has shown that the iron 
content in the SN of PD patients does not significantly influence the neuromelanin signal 
in this topography, strengthening the interpretation of neuromelanin-sensitive imaging 
and motivating the investigation of possible separate pathways of neurodegeneration in 
PD.  
The reliability of DTI metrics in the SN of PD patient’s, strengthens the future usage of 
these parameters to detect small microstructural changes in this area. The reproducibility 
of DTI metrics at the SN validate the usage of these imaging parameters in longitudinal 
evaluation, since the within-subject variability of this imaging technique is low. 
Looking at the global work presented in this dissertation the developed studies were 
pioneer in PD imaging field and have set the grounds for a different approach to PD 
neuro-imaging investigation. The group interactions that were built opened new 
possibilities and are the basis for a long term path that we hope may bring a contribution 
to the imaging study of movement disorders. The developed multi-modal imaging 
protocol, the graphic user interfaces and the imaging-clinical cooperation, can make a 
difference when looking at PD diagnosis and differential diagnosis and possibly open new 
possibilities for future research that answer new questions and pursues lines of 
investigation, with a possible impact in disease management and comprehension.  
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